United States
Securities and Exchange Commission
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the
Securities Exchange Act of 1934 (Amendment No.
)
Filed
by the Registrant ☒
Filed
by a Party other than the Registrant ☐
Check
the appropriate box:
☒ |
Preliminary Proxy
Statement |
|
|
☐ |
Confidential,
For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
|
☐ |
Definitive Proxy
Statement |
|
|
☐ |
Definitive Additional
Materials |
|
|
☐ |
Soliciting Material
Pursuant to §240.14a-12 |
AVALON
GLOBOCARE CORP.
(Name
of Registrant as Specified In Its Charter)
N/A
(Name
of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment
of Filing Fee (Check all boxes that apply):
☒ |
No fee required |
|
|
☐ |
Fee paid previously
with preliminary materials |
|
|
☐ |
Fee computed on table
in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
AVALON GLOBOCARE CORP.
4400 Route 9 South, Suite 3100
Freehold, NJ 07728
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
To be held on October 8, 2024
To the Stockholders of Avalon GloboCare Corp.:
NOTICE IS HEREBY GIVEN that the 2024 Annual
Meeting of Stockholders (the “Annual Meeting”) of Avalon GloboCare Corp. (the “Company”) will be held on Tuesday,
October 8, 2024, beginning at 9:00 a.m., Eastern Time. The Annual Meeting will be held virtually via the Internet at a virtual audio web
conference at www.virtualshareholdermeeting.com/ALBT2024. You will not be able to attend the Annual Meeting at a physical location.
At the Annual Meeting, stockholders will consider and vote on the following matters:
| (1) | To elect seven director nominees to serve as directors until
the next annual meeting of stockholders and until their successors are duly elected and qualified; |
| (2) | To ratify the appointment of M&K CPAS, PLLC as the Company’s
independent registered public accounting firm for the fiscal year ending December 31, 2024; |
| (3) | To approve the potential issuance of shares of the Company’s
common stock in excess of 19.99% of our outstanding common stock pursuant to Nasdaq listing rules; |
| (4) | To approve the amendment of the Company’s amended and restated certificate
of incorporation, as amended, to effectuate a reverse stock split of the Company’s outstanding shares of common stock, at a ratio
of no less than 1-for-2 and no more than 1-for-15, with such ratio to be determined at the sole discretion of the Board (the “Reverse
Stock Split”); |
| (5) | To approve the amendment of the Certificate of Incorporation,
which approval is contingent upon stockholder approval or, and the effectuation of, the Reverse Stock Split, to reduce the total number
of authorized shares of our common stock from 490,000,000 shares to 100,000,000 shares (the “Decrease in Authorized Shares”); |
| (6) | To approve, on an advisory basis, the compensation of the Company’s
named executive officers as disclosed in the Proxy Statement; and |
| (7) | To consider any other matters that may properly come before
the Annual Meeting. |
Proposal No. 5, the Decrease in Authorized Shares,
is contingent upon stockholder approval of Proposal No. 4 and the occurrence of the Reverse Stock Split. With respect to all other proposals,
including Proposal 4, approval of any one proposal is not dependent on stockholders approving any other proposal. Therefore, if stockholders
approve one proposal, but not others, except for Proposal No. 5, the approved proposal would still take effect.
Only stockholders who owned shares of our common
stock at the close of business on August 28, 2024 are entitled to receive notice of and to vote at the Annual Meeting or any postponement
or adjournment thereof.
Your vote is important. Whether you plan to attend
the Annual Meeting live via the Internet or not, you may vote your shares over the Internet or by marking, signing, dating and mailing
the proxy card in the envelope provided. If you attend the Annual Meeting live via the Internet and prefer to vote during the Annual Meeting,
you may do so even if you have already voted your shares. We designed the format of this year’s Annual Meeting to ensure that our
stockholders who attend the Annual Meeting live via the Internet will be afforded the same rights and opportunities to participate as
they would at an in-person meeting. You may revoke your proxy in the manner described in the Proxy Statement at any time before it has
been voted at the Annual Meeting.
|
By Order of the Board of Directors |
|
|
|
/s/ Wenzhao Lu |
|
Wenzhao Lu |
|
Chairman of the Board of Directors |
|
|
[●], 2024 |
|
Freehold, NJ |
|
PROXY STATEMENT
TABLE OF CONTENTS
AVALON GLOBOCARE CORP.
PROXY STATEMENT
FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS
GENERAL INFORMATION
This Proxy Statement contains information related
to the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of Avalon GloboCare Corp., a Delaware corporation (“Avalon”
or the “Company”), to be held on Tuesday, October 8, 2024 at 9:00 a.m., Eastern Time, or at such other time and place to which
the Annual Meeting may be adjourned or postponed. We are planning to hold the Annual Meeting virtually via the Internet, at www.virtualshareholdermeeting.com/ALBT2024.
The enclosed proxy is solicited by the Company’s Board of Directors (the “Board”). The proxy materials relating to the
Annual Meeting will first be made available to stockholders entitled to vote at the Annual Meeting on or about [●], 2024. A list
of record holders of the Company’s common stock entitled to vote at the Annual Meeting will be available for examination by any
stockholder, for any purpose germane to the Annual Meeting, at our principal offices at 4400 Route 9 South, Suite 3100, Freehold, NJ 07728,
during normal business hours for 10 days prior to the Annual Meeting.
Our proxy materials, including the Notice of
Annual Meeting, our Proxy Statement, and our Annual Report for the fiscal year ended December 31, 2023 are available on the Internet at
www.proxyvote.com.
In this Proxy Statement, the terms the “Company,”
“we,” “us,” and “our” refer to Avalon GloboCare Corp. The mailing address of our principal executive
offices is Avalon GloboCare Corp., 4400 Route 9 South, Suite 3100, Freehold, NJ 07728.
About the Meeting
Why are we calling this Annual Meeting?
We are calling the Annual Meeting to seek the
approval of our stockholders on the following matters:
| (1) | To elect seven director nominees to serve as directors until
the next annual meeting of stockholders and until their successors are duly elected and qualified; |
| (2) | To ratify the appointment of M&K CPAS, PLLC (“M&K”)
as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024; |
| (3) | To approve the potential issuance of shares of the Company’s
common stock in excess of 19.99% of our outstanding common stock pursuant to Nasdaq listing rules; |
| (4) | To approve the amendment of the Company’s amended and
restated certificate of incorporation, as amended (the “Certificate of Incorporation”), to effectuate a reverse stock split
of the Company’s outstanding shares of common stock, at a ratio of no less than 1-for-2 and no more than 1-for-15,
with such ratio to be determined at the sole discretion of the Board (the “Reverse Stock Split”); |
| (5) | To approve the amendment of the Certificate of Incorporation,
which approval is contingent upon stockholder approval or, and the effectuation of, the Reverse Stock Split, to reduce the total number
of authorized shares of our common stock from 490,000,000 shares to 100,000,000 shares (the “Decrease in Authorized Shares”); |
| (6) | To approve, on an advisory basis, the compensation of the Company’s
Named Executive Officers (as hereinafter defined) as disclosed in this Proxy Statement; and |
| (7) | To consider any other matters that may properly come before
the Annual Meeting. |
Proposal No. 5, the Decrease in Authorized Shares,
is contingent upon stockholder approval of Proposal No. 4 and the occurrence of the Reverse Stock Split. With respect to all other proposals,
including Proposal 4, approval of any one proposal is not dependent on stockholders approving any other proposal. Therefore, if stockholders
approve one proposal, but not others, except for Proposal No. 5, the approved proposal would still take effect.
What are the Board’s voting recommendations?
Our Board recommends that you vote:
| ● | “FOR” the election of each of the director
nominees identified herein (Proposal No. 1); |
| ● | “FOR” the ratification of the appointment
of M&K as our independent registered public accounting firm for the fiscal year ending December 31, 2024 (Proposal No. 2); |
| ● | “FOR”
the approval of the potential issuance of shares of the Company’s common stock in excess of 19.99% of our outstanding common stock
pursuant to Nasdaq listing rules (Proposal No. 3); |
| ● | “FOR” the approval of the amendment of the
Company’s Certificate of Incorporation to effectuate the Reverse Stock Split (Proposal No. 4); |
| ● | “FOR”
approval of the amendment of the Certificate of Incorporation to reduce the total number of authorized shares of our common stock from
490,000,000 shares to 100,000,000 shares (Proposal No. 5); and |
| ● | “FOR” the approval of the compensation of
our Named Executive Officers as disclosed in this Proxy Statement (Proposal No. 6). |
If any other matter is properly brought before
the Annual Meeting, the Company – through the individuals named in the Company’s proxy card and acting as the “proxy
holder,” or his or her designee, and pursuant to the blanket authorization granted under the proxy – will vote your shares
on that matter in accordance with the discretion and judgment of the proxy holder.
Our Board believes that the election of the director nominees identified
herein (Proposal No. 1), the appointment of M&K as our independent registered public accounting firm for the year ending December 31,
2024 (Proposal No. 2), the approval of the potential issuance of shares of the Company’s common stock in excess of 19.99% of our
outstanding common stock pursuant to Nasdaq listing rules (Proposal No. 3), the approval of the amendment of the Company’s Certificate
of Incorporation to effectuate the Reverse Stock Split (Proposal No. 4), the approval of the amendment of the Certificate of Incorporation
to reduce the total number of authorized shares of our common stock from 490,000,000 shares to 100,000,000 shares (Proposal No. 5), and
the approval of the compensation of our Named Executive Officers as disclosed in this Proxy Statement (Proposal No. 6), are advisable
and in the best interests of the Company and its stockholders, and recommends that you vote “FOR” each of the proposals.
Who is entitled to vote at the Annual Meeting?
Only stockholders of record at the close of business
on the record date, August 28, 2024 (the “Record Date”), are entitled to receive notice of the Annual Meeting and to vote
the shares of common stock that they held on that date at the Annual Meeting, or any postponement or adjournment of the Annual Meeting.
Holders of our common stock are entitled to one vote per share on each matter to be voted upon.
As of the Record Date, we had [●] outstanding
shares of common stock.
Who can attend the Annual Meeting?
All stockholders as of the Record Date, or their
duly appointed proxies, may attend the Annual Meeting. Attendance at the Annual Meeting shall solely be via the Internet at www.virtualshareholdermeeting.com/ALBT2024
using the 16-digit control number on the proxy card or voting instruction form that accompanied the proxy materials. Stockholders will
not be able to attend the Annual Meeting at a physical location.
The live webcast of the Annual Meeting will begin
promptly at 9:00 a.m., Eastern Time. Online access to the audio webcast will open approximately 30 minutes prior to the start of the Annual
Meeting to allow time for our stockholders to log in and test their devices’ audio system. We encourage our stockholders to access
the meeting in advance of the designated start time.
An online portal will be available to our stockholders
at www.proxyvote.com commencing approximately on or about [●], 2024. By accessing this portal, stockholders will be able to
vote in advance of the Annual Meeting. Stockholders may also vote, and submit questions, during the Annual Meeting on www.virtualshareholdermeeting.com/ALBT2024.
To demonstrate proof of stock ownership, you will need to enter the 16-digit control number received with your proxy card or voting instruction
form to submit questions and vote at our Annual Meeting. If you hold your shares in “street name” (that is, through a broker
or other nominee), you will need authorization from your broker or nominee in order to vote. We intend to answer questions submitted during
the Annual Meeting that are pertinent to the Company and the items being brought for stockholder vote at the Annual Meeting, as time permits,
and in accordance with the Rules of Conduct for the Annual Meeting. To promote fairness, efficiently use the Company’s resources
and ensure all stockholder questions are able to be addressed, we will respond to no more than three questions from a single stockholder.
We have retained Broadridge Financial Solutions to host our virtual annual meeting and to distribute, receive, count and tabulate proxies.
How do I attend and vote shares at the Annual
Meeting?
Your vote is important. You may vote on the Internet,
by telephone, by mail or by attending the Annual Meeting and voting electronically, all as described below. The Internet and telephone
voting procedures are designed to authenticate stockholders by use of a control number and to allow you to confirm that your instructions
have been properly recorded. If you vote by telephone or on the Internet, you do not need to return your proxy card or voting instruction
card.
Vote on the Internet
If you are a stockholder of record, you may follow
the instructions provided with your proxy materials and on your proxy card. If your shares are held with a broker, you may follow the
instructions provided with your proxy materials. Have your proxy materials in hand when you access the voting website. On the Internet
voting site, you can confirm that your instructions have been properly recorded. If you vote on the Internet, you can also request electronic
delivery of future proxy materials. Internet voting facilities are available from [●], 2024 and will be available 24 hours a day
until 11:59 p.m., Eastern Time, on October 7, 2024.
Vote by Telephone
If you are a stockholder of record, you can also
vote by telephone by dialing 1-800-690-6903. If your shares are held with a broker, you can vote by telephone by dialing the number specified
on your voting instruction card. Have your proxy card or voting instruction card in hand when you call. Internet voting facilities
are available from [●], 2024 and will be available 24 hours a day until 11:59 p.m., Eastern Time, on October 7, 2024.
Vote by Mail
You may choose to vote by mail, by marking your
proxy card or voting instruction card, dating and signing it, and returning it in the postage-paid envelope provided. If the envelope
is missing and you are a stockholder of record, please mail your completed proxy card to Vote Processing, c/o Broadridge, 51 Mercedes
Way, Edgewood, NY 11717. If the envelope is missing and your shares are held with a broker, please mail your completed voting instruction
card to the address specified therein. Please allow sufficient time for mailing if you decide to vote by mail as it must be received by
8:00 a.m., Eastern Time, on October 8, 2024.
Voting at the Annual Meeting
You will have the right to vote at the Annual
Meeting.
You will have the right to vote on the day of,
or during, the Annual Meeting on www.virtualshareholdermeeting.com/ALBT2024. To demonstrate proof of stock ownership, you will
need to enter the 16-digit control number received with your Notice, proxy card or voting instruction form to vote at our Annual Meeting.
Even if you plan to attend our Annual Meeting
remotely, we recommend that you also submit your proxy as described above so that your vote will be counted if you later decide not to
attend our Annual Meeting.
The shares voted electronically, telephonically,
or represented by the proxy cards received, properly marked, dated, signed and not revoked, will be voted at the Annual Meeting.
How can I submit a question for the Annual
Meeting?
Stockholders may submit questions in writing during
the Annual Meeting at www.virtualshareholdermeeting.com/ALBT2024. Stockholders will need their Control Number (which can be obtained
by following the procedures described under the heading “How do I attend and vote shares at the Annual Meeting?” above).
As part of the Annual Meeting, we will hold a
live question and answer session, during which we intend to answer questions submitted in writing during the Annual Meeting in accordance
with the Annual Meeting procedures which are pertinent to the Company and the Annual Meeting matters, as time permits.
What constitutes a quorum?
The presence at the Annual Meeting, in person
or by proxy, of the holders of a majority of our common stock outstanding on the Record Date will constitute a quorum for our meeting.
Pursuant to the General Corporation Law of the State of Delaware (the “DGCL”), abstentions will be counted for the purpose
of determining whether a quorum is present. If brokers have, and exercise, discretionary authority on at least one item on the agenda
for the Annual Meeting, uninstructed shares for which broker non-votes occur will constitute voting power present for the discretionary
matter and will therefore count towards the quorum.
How do I vote?
Your vote is important. On or about [●],
2024, we will begin mailing our proxy materials to all stockholders of record on our books at the close of business on the Record Date
and will post our proxy materials at www.proxyvote.com. In addition, that website provides information regarding how you may request
to receive proxy materials electronically by email, on an ongoing basis.
You may vote on the Internet, by telephone, by
mail or by attending the Annual Meeting and voting electronically, all as described below. The Internet and telephone voting procedures
are designed to authenticate stockholders by use of a control number and to allow you to confirm that your instructions have been properly
recorded. If you vote by telephone or on the Internet, you do not need to return your proxy card or voting instruction card.
What if I vote and then change my mind?
You may revoke your proxy at any time before it
is exercised by:
| ● | filing
with the Secretary of the Company a notice of revocation; |
| ● | submitting
a later-dated vote by telephone or on the Internet; |
| ● | sending
in another duly executed proxy bearing a later date; or |
| ● | attending
the Annual Meeting remotely and casting your vote in the manner set forth above. |
Your latest vote will be the vote that is counted.
What is the difference between holding shares
as a stockholder of record and as a beneficial owner?
Many of our stockholders hold their shares through
a stockbroker, bank or other nominee rather than directly in their own name. As summarized below, there are some distinctions between
shares held of record and those owned beneficially.
Stockholder of Record
If your shares are registered directly in your
name with our transfer agent, VStock Transfer LLC, you are considered, with respect to those shares, the stockholder of record. As the
stockholder of record, you have the right to directly grant your voting proxy or to vote at the Annual Meeting.
Beneficial Owner
If your shares are held in a stock brokerage account
or by a bank or other nominee, you are considered the beneficial owner of shares held in street name, and these proxy materials are being
forwarded to you by your broker, bank or nominee which is considered, with respect to those shares, the stockholder of record. As the
beneficial owner, you have the right to direct your broker as to how to vote and are also invited to attend the Annual Meeting. However,
because you are not the stockholder of record, you may not vote these shares at the Annual Meeting unless you obtain a signed proxy from
the record holder giving you the right to vote the shares. If you do not provide the stockholder of record with voting instructions or
otherwise obtain a signed proxy from the record holder giving you the right to vote the shares, broker non-votes may occur for the shares
that you beneficially own. The effect of broker non-votes is more specifically described in “What vote is required to approve
each proposal?” below.
What are “broker non-votes”?
Brokers, banks or other nominees are permitted
to use discretionary voting authority to vote for proposals that are deemed “routine” by the New York Stock Exchange, which
means that they can submit a proxy or cast a ballot on behalf of stockholders who do not provide a specific voting instruction. Brokers,
banks or other nominees are not permitted to use discretionary voting authority to vote for proposals that are deemed “non-routine”
by the New York Stock Exchange. The determination of which proposals are deemed “routine” versus “non-routine”
may not be made by the New York Stock Exchange until after the date on which this Proxy Statement has been mailed to you. As such, it
is important that you provide voting instructions to your broker, bank or other nominee as to how to vote your shares, if you wish to
ensure that your shares are present and voted at the Annual Meeting on all matters and if you wish to direct the voting of your shares
on “routine” matters.
When there is at least one “routine”
matter to be considered at a meeting, a “broker non-vote” occurs when a proposal is deemed “non-routine” and a
nominee holding shares for a beneficial owner does not have discretionary voting authority with respect to the “non-routine”
matter being considered and has not received instructions from the beneficial owner.
Each of Proposal No. 1 (election of directors),
Proposal No. 3 (approval of the potential issuance of shares of the Company’s common stock in excess of 19.99% of our outstanding
common stock pursuant to Nasdaq listing rules), Proposal No. 4 (approval of the amendment of the Company’s Certificate of Incorporation
to effectuate the Reverse Stock Split, Proposal No. 5 (approval of the amendment of the Certificate of Incorporation to reduce the total
number of authorized shares of our common stock from 490,000,000 shares to 100,000,000 shares), and Proposal No. 6 (approval of the compensation
of our Named Executive Officers as disclosed in this Proxy Statement) is generally considered to be a “non-routine” matter
and brokers, banks or other nominees are not permitted to vote on these matters if the broker, bank or other nominee has not received
instructions from the beneficial owner. Accordingly, it is particularly important that beneficial owners instruct their brokers, banks
or other nominees how they wish to vote their shares on these proposals. Proposal No. 2 (ratification of M&K as our independent registered
public accounting firm for the fiscal year ending December 31, 2024) is generally considered to be a “routine” matter, and
hence a broker, bank or other nominee may be able to vote on Proposal No. 2 even if it does not receive instructions from the beneficial
owner.
What vote is required to approve each proposal?
With respect to Proposal No. 1 (election of directors),
the directors will be elected by a plurality of the votes cast at the Annual Meeting, and the director nominees who receive the greatest
number of votes up to the maximum number of directors to be elected at the Annual Meeting will be elected. Brokers do not have discretionary
authority to vote on this matter. As a result, abstentions and “broker non-votes”, if any, will not affect the outcome of
the vote on Proposal No. 1.
With respect to Proposal No. 2 (the ratification of M&K as our independent
registered public accounting firm for our fiscal year ending December 31, 2024), Proposal No. 3 (approval of the potential issuance of
shares of the Company’s common stock in excess of 19.99% of our outstanding common stock pursuant to Nasdaq listing rules), Proposal
No. 4 (approval of the amendment of the Company’s Certificate of Incorporation to effectuate the Reverse Stock Split, Proposal No.
5 (approval of the Decrease in Authorized Shares), Proposal No. 6 (approval of the compensation of our Named Executive Officers as disclosed
in this Proxy Statement), and the approval of any other matter that may properly come before the Annual Meeting, the affirmative vote
of a majority of the votes cast by the holders of the shares of our common stock present or represented by proxy at the Annual Meeting
and voting on such proposal, is required to approve these proposals.
Proposal No. 5 (the Decrease in Authorized Shares)
is contingent upon stockholder approval of Proposal No. 4 and the occurrence of the Reverse Stock Split. With respect to all other proposals,
including Proposal 4, approval of any one proposal is not dependent on stockholders approving any other proposal. Therefore, if stockholders
approve one proposal, but not others, except for Proposal No. 5, the approved proposal would still take effect.
Abstentions will have no effect on the outcome of Proposal No. 2, Proposal
No. 3, Proposal No. 4, Proposal No. 5 or Proposal No. 6. Brokers do not have discretionary authority to vote on Proposal No. 3, Proposal
No. 4, Proposal No. 5 or Proposal No. 6, but they do have discretionary authority to vote on Proposal No. 2. Accordingly, broker non-votes
will have no effect on the outcome of Proposals No. 3, No. 4, No. 5 or No. 6, and, because Proposal No. 2 is “routine,” no
broker non-votes will occur on Proposal No. 2.
Under the DGCL, holders of the common stock will
not have any dissenters’ rights of appraisal in connection with any of the matters to be voted on at the Annual Meeting.
What happens if stockholders approve one
or more proposals but not others?
Approval of any one proposal is not dependent
on stockholders approving any other proposal, except the Decrease in Authorized Shares (Proposal No. 5) is contingent upon stockholder
approval of the Reverse Stock Split (Proposal No. 4) and the occurrence of such Reverse Stock Split. The Reverse Stock Split (Proposal
No. 4) is not contingent upon stockholder approval of the Decrease in Authorized Shares (Proposal No, 5) or any other proposal. Other
than Proposal No. 5, if stockholders approve one proposal, but not others, the approved proposal would still take effect.
Do any officers or directors have any interest
in Proposals No. 2 through No. 5?
No officer or director has any substantial interest,
direct or indirect, by security holdings or otherwise, in any of Proposals No. 2 through No. 5 that is not shared by all of our other
stockholders.
How are we soliciting this proxy?
We are soliciting this proxy on behalf of our
Board and will pay all expenses associated therewith. Some of our officers, directors and other employees also may, but without compensation
other than their regular compensation, solicit proxies by further mailing or personal conversations, or by telephone, facsimile or other
electronic means.
We will also, upon request, reimburse brokers
and other persons holding stock in their names, or in the names of nominees, for their reasonable out-of-pocket expenses for forwarding
proxy materials to the beneficial owners of the capital stock and to obtain proxies.
PROPOSAL NO. 1: TO
ELECT SEVEN DIRECTORS TO SERVE UNTIL THE NEXT ANNUAL MEETING AND UNTIL THEIR SUCCESSORS HAVE BEEN DULY ELECTED AND QUALIFIED
Our Board is currently composed of seven directors.
Vacancies on the Board may be filled only by persons elected by a majority of the remaining directors then in office, even if less than
a quorum of the Board. A director elected by the Board to fill a vacancy, including vacancies created by an increase in the number of
directors, shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until
such director’s successor shall have been duly elected and qualified or until his or her earlier resignation, death or removal.
Each of the nominees listed below is currently
one of our directors. If elected at the Annual Meeting, each of these nominees would serve until the next annual meeting and until his
or her successor has been duly elected and qualified, or, if sooner, until his or her earlier resignation, death or removal.
Directors are elected by a plurality of the
votes cast by the holders of shares present in person or represented by proxy and entitled to vote on the election of directors at
the Annual Meeting. Abstentions and broker non-votes will not be treated as a vote for or against any particular director nominee
and will not affect the outcome of the election. Stockholders may not vote, or submit a proxy, for a greater number of nominees than
the seven nominees named below. The director nominees receiving the highest number of affirmative votes will be elected. Shares
represented by executed proxies will be voted, if authority to do so is not withheld, for the election of the seven director
nominees named below. If any director nominee becomes unavailable for election as a result of an unexpected occurrence, shares that
would have been voted for that nominee will instead be voted for the election of a substitute nominee proposed by our Board. Each
person nominated for election has agreed to serve if elected. Our management has no reason to believe that any nominee will be
unable to serve.
Nominees for Election until the Next Annual
Meeting
The following table sets forth the name, age,
position and tenure of each of our directors who are up for re-election at the Annual Meeting:
Name |
|
Age |
|
Position |
Wenzhao Lu |
|
66 |
|
Chairman of the Board of Directors |
David Jin, M.D., Ph.D. |
|
56 |
|
Chief Executive Officer, President and Director |
Lourdes Felix |
|
56 |
|
Director |
Steven A. Sanders |
|
79 |
|
Director |
William B. Stilley, III |
|
56 |
|
Director |
Wilbert J. Tauzin II |
|
81 |
|
Director |
Tevi Troy |
|
56 |
|
Director |
The following includes a brief biography of each
of the nominees standing for election to the Board at the Annual Meeting, based on information furnished to us by each director nominee,
with each biography including information regarding the experiences, qualifications, attributes or skills that caused the Nominating and
Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”) and the Board to determine
that the applicable nominee should serve as a member of our Board.
Wenzhao
Lu. Mr. Lu has served as our Chairman of the Board since October 10, 2016. He is a seasoned healthcare entrepreneur with extensive
operational knowledge and experience in the U.S. and Asia. He served as chairman of the board of directors of the Daopei Medical Group
(“DPMG”) from 2010 to 2021. Under his leadership, DPMG operated three top-ranked private hospitals (located in Beijing and
Hebei), specialty hematology laboratories, and a hematology research institute, with more than 100 partnering and collaborating hospitals
in China. DPMG was founded by Professor Daopei Lu, a renowned hematologist pioneering in hematopoietic stem cell transplant and a member
of the Academy of Engineering in China. Mr. Lu received a Bachelor of Arts from Temple University Tyler School of Arts in 1988 and subsequently
worked as senior Art Director at Ogilvy & Mather Advertising Company. In 2009, prior to joining DPMG, Mr. Lu served as Chief Operating
Officer of BioTime Asia Limited, a subsidiary of BioTime, Inc. (NYSE American: BTX). We believe Mr. Lu is qualified to serve as a director
because of his extensive operational knowledge of, and executive level management experience in, the healthcare industry.
David
Jin. Dr. Jin has served as our Chief Executive Officer, President and as a member of our Board since September 14, 2016. From 2009
to 2017, Dr. Jin served as the Chief Medical Officer of BioTime, Inc. (NYSE American: BTX), a clinical stage regenerative medicine company
with a focus on pluripotent stem cell technology. Dr. Jin also acts as a senior translational clinician-scientist at the Howard Hughes
Medical Institute and the Ansary Stem Cell Center at Weill Cornell Medical College of Cornell University. Dr. Jin previously served as
Chief Consultant/Advisor for various biotech/pharmaceutical companies regarding hematology, oncology, immunotherapy and stem cell-based
technology development. Dr. Jin has been Principal Investigator in more than 15 pre-clinical and clinical trials, as well as an author/co-author
of over 80 peer-reviewed scientific abstracts, articles, reviews, and book chapters. Dr. Jin studied medicine at SUNY Downstate College
of Medicine in Brooklyn, New York. He received his clinical training and subsequent faculty tenure at the New York-Presbyterian Hospital
(the teaching hospital for both Cornell and Columbia Universities) in the areas of internal medicine, hematology, and clinical oncology.
Dr. Jin was honored as Top Chief Medical Officer by ExecRank in 2012, as well as recognized by Leading Physicians of the World in 2015.
We believe Dr. Jin is qualified to serve as a director because of his role with us, and his extensive operational knowledge of, and executive
level management experience in, the healthcare industry.
Lourdes
Felix. Lourdes Felix has served as a member of the Board since January 9, 2023. Ms. Felix is an entrepreneur and corporate finance
executive with 30 years of combined experience in capital markets, public accounting and in the private sector. She presently serves as
Chief Executive Officer, Chief Financial Officer, and a member of the board of directors of BioCorRx, Inc., a company focused on addiction
treatment solutions and related disorders. She has been with BioCorRx, Inc. since October 2012. Ms. Felix is one of the founders and President
of BioCorRx Pharmaceuticals Inc., a majority owned subsidiary of BioCorRx, Inc. Prior to joining BioCorRx, Inc., her experience was in
the private sector and public accounting. Ms. Felix has expertise in finance, accounting, company-wide operations, budgeting, and internal
control principles including GAAP, SEC, and SOX Compliance. She has thorough knowledge of federal and state regulations and has successfully
managed and produced SEC regulatory filings. She also has extensive experience in developing and managing financial operations. Ms. Felix
holds a Bachelor of Science degree in Accounting from the University of Phoenix. She continued her education and is an MBA candidate at
D’Amore-McKim School of Business, Northeastern University. Ms. Felix is qualified to serve as a director because of her extensive
investment and executive level management experience.
Steven
A. Sanders. Mr. Sanders has served as a member of the Board since July 30, 2018. Since January 2017, Mr. Sanders has been Of Counsel
to the law firm of Ortoli Rosenstadt LLP. From July 2007 until January 2017, Mr. Sanders was a Senior Partner at Ortoli Rosenstadt LLP.
From January 1, 2004 until June 30, 2007, he was Of Counsel to the law firm of Rubin, Bailin, Ortoli, LLP. From January 1, 2001 to December
31, 2003, he was Counsel at the law firm of Spitzer & Feldman PC. Mr. Sanders also serves as a member of the board of directors of
Helijet International, Inc. From March 2018 to January 2024, he also served as a director of ElectraMeccanica Vehicles Corp., previously
a Nasdaq-listed company. Additionally, since October 2013, he has been a member of the board of directors at the American Academy of Dramatic
Arts, and, since February 2015, has been a member of the board of directors of the Bay Street Theater. Mr. Sanders received his JD from
Cornell University and his BBA from The City College of New York. We believe Mr. Sanders is qualified to serve as a director because of
his corporate, securities and international law experience, including working with companies in the life sciences industry.
William
B. Stilley, III. Mr. Stilley has served as a member of the Board since July 5, 2018. Mr. Stilley has been the Chief Executive Officer
of Adovate, LLC since January 2023. Previously, he was Chief Executive Officer of Purnovate, Inc., a subsidiary of Adial Pharmaceuticals,
Inc. (“Adial”), from January 2021 until May 2023, was Chief Executive Officer of Adial from December 2010 until August 2022,
and continues as a member of Adial’s board of directors, which he joined in December 2010. From July 2021 to October 2022, Mr. Stilley
served as a member of the board of directors and chairman of the audit committee of Sysorex, Inc. From August 2008 until December 2010,
he was the Vice President, Business Development and Strategic Projects at Clinical Data, Inc. (NASDAQ: CLDA). Mr. Stilley was the COO
and CFO of Adenosine Therapeutics, LLC until certain assets of Adenosine Therapeutics were acquired by Clinical Data, Inc. in August 2008.
Mr. Stilley has advised both public and private companies on financing and M&A transactions, has been the interim CFO of a public
company, the interim Chief Business Officer and then Advisor for Diffusion Pharmaceuticals from September 2015 through March 2018, the
audit chair for a public company, and the COO and CFO of a number of private companies. Before entering the business community, Mr. Stilley
served as Captain in the U.S. Marine Corps. Mr. Stilley has an MBA with honors from the Darden School of Business and a B.S. in Commerce/Marketing
from the McIntire School of Commerce at the University of Virginia. He currently serves on the Advisory Board of Virginia BIO, the statewide
biotechnology organization. We believe Mr. Stilley is qualified to serve as a director because of his extensive knowledge of the biotechnology
industry, significant executive leadership and operational experience, and knowledge of, and experience in, financing and M&A transactions.
Wilbert
J. Tauzin II. Mr. Tauzin has served as a member of the Board since November 1, 2017. From December 2010 until March 1, 2014, Congressman
Tauzin served as a Special Legislative Counsel at Alston & Bird LLP. From December 2004 to June 2010, Congressman Tauzin was President
and Chief Executive Officer of Pharmaceutical Research and Manufacturers of America, a trade group that serves as one of the pharmaceutical
industry’s top lobbying groups. He served 12.5 terms in the U.S. House of Representatives, representing Louisiana’s 3rd Congressional
District. From January 2001 through February 2004, Congressman Tauzin served as Chairman of the House Committee on Energy and Commerce.
He also served as a senior member of the House Resources Committee and Deputy Majority Whip. Prior to serving as a member of Congress,
Congressman Tauzin was a member of the Louisiana State Legislature, where he served as Chairman of the House Natural Resources Committee
and Chief Administration Floor Leader. He served as Lead Independent Director of LHC Group, a publicly traded provider of quality home
health care, from 2005 to 2021 and retains the role of Lead Independent Emeritus today. The Congressman also served on the board of directors
of Entergy, a Fortune 500 company. In addition, the Congressman chartered a Louisiana State Savings and Loan Association and Chaired its
first board of directors. He received a Bachelor of Arts Degree from Nicholls State University and a Juris Doctor degree from Louisiana
State University. We believe Congressman Tauzin is qualified to serve as a director because of his extensive knowledge of the pharmaceutical
industry and his experience as a director of several publicly traded and privately held companies.
Tevi Troy. Dr. Troy has served as a member
of the Board since June 4, 2018. He is a former Deputy Secretary of the U.S. Department of Health and Human Services. Dr. Troy is a Senior
Fellow at the Bipartisan Policy Center in Washington. He was the founder and CEO of the American Health Policy Institute and a Senior
Fellow at Hudson Institute. On August 3, 2007, Dr. Troy was unanimously confirmed by the U.S. Senate as the Deputy Secretary of HHS.
As Deputy Secretary, Dr. Troy was the chief operating officer of the largest civilian department in the federal government, with a budget
of $716 billion and over 67,000 employees. Dr. Troy has extensive White House experience, having served in several high-level positions
over a five-year period, culminating in his service as Deputy Assistant and then Acting Assistant to the President for Domestic Policy.
Dr. Troy has held high-level positions on Capitol Hill as well. From 1998 to 2000, Dr. Troy served as the Policy Director for Senator
John Ashcroft. From 1996 to 1998, Dr. Troy was Senior Domestic Policy Adviser and later Domestic Policy Director for the House Policy
Committee, chaired by Christopher Cox. In addition to his senior level government work and health care expertise, Dr. Troy is also a
best-selling presidential historian and the author of five books, including, most recently, “The Power and the Money: Epic Clashes
Between Commanders in Chief and Titans of Industry.” Dr. Troy’s many other affiliations include contributing editor for Washingtonian
magazine; member of the publication committee of National Affairs; member of the Board of Fellows of the Jewish Policy Center; a Senior
Fellow at the Potomac Institute; and a member of the Bipartisan Commission on Biodefense. Dr. Troy has a B.S. in Industrial and Labor
Relations from Cornell University and an M.A. and Ph.D. in American Civilization from the University of Texas at Austin. We believe Dr.
Troy is qualified to serve as a director because of his extensive knowledge of the healthcare industry and his significant leadership
experience.
Board Diversity Matrix
The following Board Diversity Matrix presents
our Board diversity statistics in accordance with The Nasdaq Stock Market LLC’s (“Nasdaq”) Rule 5606. The information
is based on our directors’ self-reporting.
Board Diversity Matrix (As of the Record Date)
Total Number of Directors - 7
| |
Female | | |
Male | | |
Non-Binary | | |
Did Not Disclose Gender | |
Directors | |
| 1 | | |
| 6 | | |
| — | | |
| — | |
Number of Directors who identify in Any of the Categories Below: | |
| | | |
| | | |
| | | |
| | |
African American or Black | |
| — | | |
| — | | |
| — | | |
| — | |
Alaskan Native or Native American | |
| — | | |
| — | | |
| — | | |
| — | |
Asian | |
| — | | |
| 2 | | |
| — | | |
| — | |
Hispanic or Latinx | |
| 1 | | |
| — | | |
| — | | |
| — | |
Native Hawaiian or Pacific Islander | |
| — | | |
| — | | |
| — | | |
| — | |
White | |
| — | | |
| 3 | | |
| — | | |
| — | |
Two or More Races or Ethnicities | |
| — | | |
| — | | |
| — | | |
| — | |
LGBTQ+ | |
| — | | |
| — | | |
| — | | |
| — | |
Did Not Disclose Demographic Background | |
| — | | |
| — | | |
| — | | |
| 1 | |
Other | |
| — | | |
| — | | |
| — | | |
| — | |
THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS
VOTE “FOR” THE ELECTION OF THE DIRECTOR NOMINEES.
CORPORATE GOVERNANCE
Composition of Board of Directors
Our Board is currently composed of seven directors.
Our directors hold office until their successors have been elected and qualified or until the earlier of their resignation or removal.
We have no formal policy regarding board diversity.
Our priority in selection of board members is identification of members who will further the interests of our stockholders through his
or her established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board
members, knowledge of our business and understanding of the competitive landscape.
A majority of the authorized number of directors
constitutes a quorum of the Board for the transaction of business. However, any action required or permitted to be taken by the Board
may be taken without a meeting if all members of the Board individually or collectively consent in writing to the action.
Board of Directors Meetings
The
primary responsibility of our Board is to provide oversight, strategic guidance, counseling, and direction to our management team. Our
Board meets on a regular basis and additionally as required. Our Board met three times in 2023. Each of the directors attended at least
75% of the aggregate of (i) the total number of meetings of our Board (held during the period for which such directors served on the
Board) and (ii) the total number of meetings of all committees of our Board on which the director served (during the periods for which
the director served on such committee or committees). We do not
have a formal policy requiring members of the Board to attend our annual meetings. Our last annual meeting of stockholders was held on
September 12, 2023. Two of our directors attended the 2023 annual meeting. We expect that all directors will attend the 2024 Annual Meeting.
Director Independence
Our common stock is listed on The NASDAQ Capital
Market. Under the rules of The NASDAQ Capital Market, independent directors must comprise a majority of our Board. In addition, the rules
of The NASDAQ Capital Market require that all the members of such committees be independent. Members of our Audit Committee, as defined
below, must also satisfy the independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended (the
“Exchange Act”). Compensation committee members must also satisfy the independence criteria established by The NASDAQ Capital
Market in accordance with Rule 10C-1 under the Exchange Act. Under the rules of The NASDAQ Capital Market, a director will only qualify
as an “independent director” if, among other qualifications, in the opinion of that company’s board of directors, that
person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities
of a director.
Our Board undertook a review of its composition,
the composition of its committees and the independence of each director. Based upon information requested from and provided by each director
concerning his or her background, employment and affiliations, including family relationships, our Board has determined that Steven A.
Sanders, Lourdes Felix, William B. Stilley, III and Tevi Troy do not, respectively, have a relationship that would interfere with the
exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is “independent”
as that term is defined under the Rules of The NASDAQ Capital Market and the Securities and Exchange Commission (the “SEC”).
In making this determination, our Board considered
the relationships that each non-employee director has with our Company and all other facts and circumstances our Board deemed relevant
in determining their independence.
Board Committees
Our Board has established an audit committee,
a compensation committee and a nominating and corporate governance committee. Our Board may establish other committees to facilitate the
management of our business. The composition and functions of each committee named above are defined and described below. Members serve
on these committees until their resignation or until as otherwise determined by our Board.
Audit Committee.
We have a separately designated standing audit committee of the Board (the “Audit Committee”), established in accordance with
Section 3(a)(58)(A) of the Exchange Act. Our Audit Committee consists of Mr. Stilley, Mr. Sanders and Dr. Troy, with Mr. Stilley serving
as the Chair of the Audit Committee. Our Board has determined that each director currently serving on our Audit Committee is an “independent
director” as defined by The NASDAQ Capital Market applicable to members of an audit committee and Rule 10A-3(b)(i) under the Exchange
Act. In addition, Mr. Stilley is an “audit committee financial expert” as defined in Item 407(d)(5) of Regulation S-K and
demonstrates “financial sophistication” as defined in Nasdaq rules. The Audit Committee is appointed by our Board to assist
with monitoring (i) the integrity of our financial statements, (ii) our compliance with legal and regulatory requirements, and (iii) the
independence and performance of our internal and external auditors.
The principal functions and responsibilities of
our Audit Committee include:
| ● | reviewing
our annual audited financial statements with management and our independent auditors, including
major issues regarding accounting and auditing principles and practices and financial reporting
that could significantly affect our financial statements; |
| ● | reviewing
our quarterly financial statements with management and our independent auditor prior to the
filing of our Quarterly Reports on Form 10-Q, including the results of the independent auditors’
reviews of the quarterly financial statements; |
| ● | recommending
to the Board the appointment of, and continued evaluation of the performance of, our independent
auditor; |
| ● | approving
and conducting a review of all related party transactions for potential conflict of interest
situations on an ongoing basis; |
| ● | approving
the fees to be paid to our independent auditor for audit services and approving the retention
of our independent auditor for non-audit services and all fees for such services; |
| ● | reviewing
periodic reports from our independent auditor regarding our auditor’s independence,
including discussion of such reports with the auditor; |
| ● | reviewing
the adequacy of our overall control environment, including internal financial controls and
disclosure controls and procedures; and |
| ● | reviewing
with our management and legal counsel legal matters that may have a material impact on our
financial statements or our compliance policies and any material reports or inquiries received
from regulators or governmental agencies. |
During the fiscal year
ended December 31, 2023, the Audit Committee met four times. The Audit Committee is governed by a written charter, as adopted by the Board.
A copy of the Audit Committee Charter is posted under the “Investors” tab under “Corporate Governance” on our
website, which is located at www.avalon-globocare.com.
Compensation
Committee. The compensation committee of the Board (the “Compensation Committee”) consists of Ms. Felix, Mr.
Sanders and Dr. Troy, with Ms. Felix serving as the Chair of the Compensation Committee. The Board has determined that each member of
the Compensation Committee is considered (i) an “independent director” as defined by Nasdaq rules applicable to members of
a compensation committee; (ii) a “non-employee director” as defined in Rule 16b-3 promulgated under the Exchange Act; and
(iii) an “outside director” as that term is defined in Section 162(m) of the Internal Revenue Code of 1986, as amended (the
“Code”). The Compensation Committee is responsible for establishing the compensation of our senior management, including salaries,
bonuses, termination arrangements, and other executive officer benefits as well as director compensation. The Compensation Committee also
administers our equity incentive plans. The Compensation Committee works with the Chairman of the Board and our Chief Executive Officer
and reviews and approves compensation decisions regarding senior management, including compensation levels and equity incentive awards.
The Compensation Committee also approves employment and compensation agreements with our key personnel and directors. The Compensation
Committee has the power and authority to conduct or authorize studies, retain independent consultants, accountants or others, and obtain
unrestricted access to management, our internal auditors, human resources and accounting employees and all information relevant to its
responsibilities.
The principal functions
and responsibilities of the Compensation Committee include:
|
● |
reviewing and approving the Company’s compensation guidelines and structure;
|
|
● |
reviewing and approving, on an annual basis, the corporate goals and objectives with respect to compensation for the Chief Executive Officer;
|
|
● |
reviewing and approving, on an annual basis, the evaluation process and compensation structure for the Company’s other officers, including salary, bonus, incentive and equity compensation;
|
|
● |
periodically reviewing and making recommendations to the Board regarding the compensation of non-management directors; and
|
|
● |
developing the executive compensation philosophy and reviewing and recommending to the Board for approval all compensation policies and compensation programs for the executive team. |
During the fiscal year
ended December 31, 2023, the Compensation Committee did not meet. The Compensation Committee is governed by a written charter, as adopted
by our Board. A copy of the Compensation Committee Charter is posted under the “Investors” tab under “Corporate Governance”
on our website, which is located at www.avalon-globocare.com.
Nominating
and Corporate Governance Committee. Our Nominating and Corporate Governance Committee consists of Mr. Sanders, Mr. Stilley
and Dr. Troy, with Mr. Sanders serving as the Chair of our Nominating and Corporate Governance Committee. Our Board has determined that
each member of the Nominating and Governance Committee is an “independent director” as defined by Nasdaq rules. The Nominating
and Corporate Governance Committee is generally responsible for recommending to our full Board certain policies, procedures, and practices
designed to ensure that our corporate governance policies, procedures, and practices continue to assist the Board and our management in
effectively and efficiently promoting the best interests of our stockholders. The Nominating and Corporate Governance Committee is also
responsible for selecting and recommending for approval by our Board and our stockholders a slate of director nominees for election at
each of our annual meetings of stockholders, and otherwise for determining the board committee members and chairpersons, subject to ratification
by our Board, as well as recommending to the Board director nominees to fill vacancies or new positions on the Board or its committees
that may occur or be created from time to time, all in accordance with our bylaws and applicable law.
In identifying independent
candidates, with significant senior-level professional experience, to be nominated as potential members of our Board, the Nominating and
Corporate Governance Committee solicits candidates from the Board, senior management and others, and may engage a search firm in the process.
The Nominating and Corporate Governance Committee reviews and narrows the list of candidates and interviews potential nominees. The final
candidate is also introduced and interviewed by the Board and the lead director if one has been appointed. In general, in considering
whether to recommend any particular candidate for inclusion in our Board’s slate of recommended director nominees, the Nominating
and Corporate Governance Committee will apply the criteria set forth in our corporate governance guidelines. These criteria include the
candidate’s integrity, business acumen, commitment to understanding our business and industry, experience, conflicts of interest
and the ability to act in the interests of our stockholders. Further, specific consideration is given to, among other things, diversity
of background and experience that a candidate would bring to our Board. The Nominating and Corporate Governance Committee does not assign
specific weights to particular criteria and no particular criterion is a prerequisite for each prospective nominee. We believe that the
backgrounds and qualifications of our directors, considered as a group, should provide a composite mix of experience, knowledge and abilities
that will allow our Board to fulfill its responsibilities. Stockholders may recommend individuals to the Nominating and Corporate Governance
Committee for consideration as potential director candidates by submitting the names, together with appropriate biographical information
and background materials to our Nominating and Corporate Governance Committee. The Nominating and Corporate Governance Committee considers
recommendations from stockholders if submitted in a timely manner in accordance with the procedures set forth in our bylaws and will apply
the same criteria to all persons being considered.
The principal functions
and responsibilities of the Nominating and Corporate Governance Committee include:
| ● | developing
and maintaining our corporate governance policy guidelines; |
| ● | developing
and maintaining our Code of Business Conduct and Ethics; |
| ● | overseeing
the interpretation and enforcement of our Code of Business Conduct and Ethics for the Chief
Executive Officer and senior financial and accounting officers; |
| ● | evaluating
the performance of our Board, its committees, and committee chairpersons and our directors;
and |
| ● | selecting
and recommending a slate of director nominees for election at each of our annual meetings
of the stockholders and recommending to the Board director nominees to fill vacancies or
new positions on the Board or its committees that may occur from time to time. |
During the fiscal year
ended December 31, 2023, the Nominating and Corporate Governance Committee met one time. The Nominating and Corporate Governance Committee
is governed by a written charter approved by our Board. A copy of the Nominating and Corporate Governance Committee Charter is posted
under the “Investors” tab under “Corporate Governance” on our website, which is located at www.avalon-globocare.com.
Stockholder Nominations for Directorships
Stockholders may recommend individuals to the
Nominating and Corporate Governance Committee for consideration as potential director candidates by submitting their names and background
to the Secretary of the Company at the address set forth below under “Stockholder Communications” in accordance with the provisions
set forth in our bylaws. All such recommendations will be forwarded to the Nominating and Corporate Governance Committee, which will review
and only consider such recommendations if appropriate biographical and other information is provided, including, but not limited to, the
items listed below, on a timely basis. All security holder recommendations for director candidates must be received by the Company in
the timeframe(s) set forth under the heading “Stockholder Proposals” below.
| ● | the
name and address of record of the security holder; |
| ● | a
representation that the security holder is a record holder of the Company’s securities,
or if the security holder is not a record holder, evidence of ownership in accordance with
Rule 14a-8(b)(2) of the Exchange Act; |
| ● | the
name, age, business and residential address, educational background, current principal occupation
or employment, and principal occupation or employment for the preceding five (5) full fiscal
years of the proposed director candidate; |
| ● | a
description of the qualifications and background of the proposed director candidate and a
representation that the proposed director candidate meets applicable independence requirements; |
| ● | a
description of any arrangements or understandings between the security holder and the proposed
director candidate; and |
| ● | the
consent of the proposed director candidate to be named in the proxy statement relating to
the Company’s annual meeting of stockholders and to serve as a director if elected
at such annual meeting. |
Assuming that appropriate information is provided
for candidates recommended by stockholders, the Nominating and Corporate Governance Committee will evaluate those candidates by following
substantially the same process, and applying substantially the same criteria, as for candidates submitted by members of the Board or other
persons, as described above and as set forth in its written charter.
Board Leadership Structure and Role in Risk
Oversight
The positions of our Chairman of the Board and
Chief Executive Officer are separated. Separating these positions allows our Chief Executive Officer to focus on our day-to-day business,
while allowing the Chairman of the Board to lead our Board in its fundamental role of providing advice to and independent oversight of
management. Our Board recognizes the time, effort and energy that the Chief Executive Officer must devote to his position in the current
business environment, as well as the commitment required to serve as our Chairman, particularly as our Board’s oversight responsibilities
continue to grow. Our Board also believes that this structure ensures a greater role for the independent directors in the oversight of
our Company and active participation of the independent directors in setting agendas and establishing priorities and procedures for the
work of our Board. Our Board believes its administration of its risk oversight function has not affected its leadership structure.
Although our bylaws do not require our Chairman
and Chief Executive Officer positions to be separate, our Board believes that having separate positions is the appropriate leadership
structure for us at this time and demonstrates our commitment to good corporate governance.
Risk is inherent with every business, and how
well a business manages risk can ultimately determine its success. We face a number of risks, including those described under the section
entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and other reports filed
with the SEC, as the same may be updated from time to time. Our Board is actively involved in oversight of risks that could affect us.
This oversight is conducted primarily by our full Board, which has responsibility for general oversight of risks.
Our Board will satisfy this responsibility through
full reports by each committee chair regarding the committee’s considerations and actions, as well as through regular reports directly
from officers responsible for oversight of particular risks within our Company. Our Board believes that full and open communication between
management and our Board is essential for effective risk management and oversight.
Stockholder Communications
Our Board will give appropriate attention to written
communications that are submitted by stockholders and will respond if and as appropriate. Absent unusual circumstances or as contemplated
by committee charters, and subject to advice from legal counsel, the Secretary of the Company is primarily responsible for monitoring
communications from stockholders and for providing copies or summaries of such communications to the Board as he considers appropriate.
Communications from stockholders will be forwarded
to all directors if they relate to important substantive matters or if they include suggestions or comments that the Secretary considers
to be important for the Board to know. Communication relating to corporate governance and corporate strategy are more likely to be forwarded
to the Board than communications regarding personal grievances, ordinary business matters, and matters as to which the Company tends to
receive repetitive or duplicative communications.
Stockholders who wish to send communications to
the Board should address such communications to: The Board of Directors, Avalon GloboCare Corp., 4400 Route 9 South, Suite 3100, Freehold,
NJ 07728, Attention: Secretary.
Code of Business Conduct and Ethics
We have adopted a written Code of Business Conduct
and Ethics that applies to our employees, officers and directors. A copy of the code is posted under the “Investors” tab under
“Corporate Governance—Governance Documents” on our website, which is located at www.avalon-globocare.com. We
intend to disclose future amendments to certain provisions of our Code of Business Conduct and Ethics, or waivers of such provisions applicable
to any principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar
functions, and our directors, on our website identified above or in filings with the SEC.
Anti-Hedging Policy
Under the terms of our insider trading policy,
we prohibit each officer, director and employee, and each of their family members and controlled entities, from engaging in certain forms
of hedging or monetization transactions. Such transactions include those, such as zero-cost collars and forward sale contracts, that would
allow them to lock in much of the value of their stock holdings, often in exchange for all or part of the potential for upside appreciation
in the stock, and to continue to own the covered securities but without the full risks and rewards of ownership.
Limitation of Director Liability and Indemnification
The DGCL authorizes corporations to limit or eliminate,
subject to certain conditions, the personal liability of directors to corporations and their stockholders for monetary damages for breach
of their fiduciary duties. Our Certificate of Incorporation limits the liability of our directors to the fullest extent permitted by Delaware
law. In addition, we have entered into indemnification agreements with each of our directors and officers whereby we have agreed to indemnify
those directors and officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred
in legal proceedings to which the director or officer was, or is threatened to be made, a party by reason of the fact that such director
or officer is or was a director, officer, employee or agent of the Company, provided that such director or officer acted in good faith
and in a manner that the director or officer reasonably believed to be in, or not opposed to, the best interests of the Company.
We have director and officer liability insurance
to cover liabilities our directors and officers may incur in connection with their services to us, including matters arising under the
Securities Act of 1933, as amended (the “Securities Act”). Our Certificate of Incorporation and bylaws also provide that we
will indemnify our directors and officers who, by reason of the fact that he or she is one of our officers or directors, is involved in
any action, suit or proceeding, whether civil, criminal, administrative or investigative related to their board role with us.
There is no pending litigation or proceeding involving
any of our directors, officers, employees or agents in which indemnification will be required or permitted. We are not aware of any threatened
litigation or proceeding that may result in a claim for such indemnification.
INFORMATION CONCERNING EXECUTIVE OFFICERS
The following table sets forth certain information
regarding our current executive officers:
Name |
|
Age |
|
Position(s) |
|
Serving in
Position
Since |
|
David Jin, M.D., Ph.D. |
|
56 |
|
Chief Executive Officer, President and Director |
|
2016 |
|
Luisa Ingargiola |
|
58 |
|
Chief Financial Officer |
|
2017 |
|
Meng Li |
|
46 |
|
Chief Operating Officer and Secretary |
|
2016 |
|
Our executive officers are elected by, and serve
at the discretion of, our Board. The business experience for the past five years, and in some instances, for prior years, of each of our
executive officers is as follows:
David Jin, M.D., Ph.D., Chief Executive Officer and Director.
See description under “Proposal No. 1”.
Luisa Ingargiola, Chief Financial Officer.
Ms. Ingargiola has served as our Chief Financial Officer since February 21, 2017. Ms. Ingargiola has significant experience serving
as Chief Financial Officer or Audit Chair for multiple Nasdaq and New York Stock Exchange companies. She currently serves as Director
and Audit Chair for several public companies, including Dragonfly Energy (DFLI) and Vision Marine (VMAR) She also serves as Director
for XOS Trucks (XOS). From March 2018 to January 2024, she served as a director of ElectraMeccanica Vehicles Corp., previously a Nasdaq-listed
company and has held several other roles as Director as Audit Chair for several public companies. From 2007 through 2016, Ms. Ingargiola
served as the Chief Financial Officer and then a member of the board of directors at MagneGas Corporation (Nasdaq: MNGA). Prior to 2007,
Ms. Ingargiola held various roles as Budget Director and Investment Analyst in several private companies. Ms. Ingargiola graduated in
1989 from Boston University with a Bachelor’s degree in Business Administration and a concentration in Finance. In 1996, she received
her MBA in Health Administration from the University of South Florida. Ms. Ingargiola is qualified to serve as a Chief Financial Officer
because of her extensive knowledge corporate governance, regulatory requirements, executive leadership and knowledge of, and experience
in, financing and M&A transactions.
Meng Li, Chief Operating Officer and Secretary.
Ms. Meng Li has served as our Chief Operating Officer and Secretary since October 10, 2016 and served as a member of the Board
from October 10, 2016 to July 9, 2018 and from April 5, 2019 through December 30, 2022. Ms. Li has over 15 years of executive experience
in international marketing, branding, communications, and media investment consultancy. Ms. Li served as Managing Director at Maxus/GroupM
(a WPP Group company) where she was responsible for business P&L and corporate management from 2006 to 2015. Prior to joining Maxus/Group
M, Ms. Li worked for Zenith Media (a Publicis Group company) from 2000 to 2006 as Senior Manager. Ms. Li received a Bachelor of Arts in
International Economic Law from Dalian Maritime University in China.
EXECUTIVE COMPENSATION
We are currently a “smaller
reporting company” and as such, we have opted to comply with the scaled down disclosure rules applicable to a “smaller reporting
company,” as such term is defined in the rules promulgated under the Securities Act, which require compensation disclosure
for (i) our principal executive officer, (ii) our two most highly compensated executive officers, other than the principal executive officer,
whose total compensation for 2023 exceeded $100,000 and who were serving as executive officers as of December 31, 2023, and (iii) up to
two additional individuals for whom disclosure would have been provided pursuant to the foregoing clause (ii) but for the fact that the
individual was not serving as an executive officer as of December 31, 2023. We refer to these individuals as “named executive officers”
or “NEOs.” Our named executive officers for the year ended December 31, 2023 were:
2023 Summary Compensation
Table
Name and Principal Position | |
Year | | |
Salary | | |
Stock Awards | | |
Option Awards | |
Nonequity Incentive Plan Compensation | | |
Nonqualified Deferred Compensation Earnings | |
All Other Compensation | | |
Total |
| |
| | |
($) | | |
($) | | |
($) | |
($) | | |
($) | |
($) | | |
($) |
Dr. David Jin | |
| 2023 | | |
| 330,000 | | |
| - | | |
- | |
| - | | |
- | |
| - | | |
330,000 |
Chief Executive Officer | |
| 2022 | | |
| 360,000 | | |
| - | | |
- | |
| - | | |
- | |
| - | | |
360,000 |
Luisa Ingargiola | |
| 2023 | | |
| 350,000 | | |
| - | | |
- | |
| - | | |
- | |
| - | | |
350,000 |
Chief Financial Officer | |
| 2022 | | |
| 350,000 | | |
| - | | |
- | |
| - | | |
- | |
| - | | |
350,000 |
Meng Li | |
| 2023 | | |
| 280,244 | | |
| - | | |
- | |
| - | | |
- | |
| - | | |
280,244 |
Chief Operating Officer | |
| 2022 | | |
| 340,000 | | |
| - | | |
- | |
| - | | |
- | |
| - | | |
340,000 |
Employment Agreements
David Jin
On December 1, 2016,
the Company entered into an Executive Employment Agreement with David Jin, the Company’s CEO and President. Pursuant to the agreement,
Mr. Jin was employed as President and Chief Executive Officer of the Company, which agreement had a term initially through November 30,
2017 unless earlier terminated pursuant to the terms of the agreement. On February 20, 2020, the Company entered into a Letter Agreement
with Dr. Jin pursuant to which the term of Dr. Jin’s Executive Employment Agreement was extended an additional three years. During
the term of the agreement, Dr. Jin is entitled to a base salary and will be eligible for a discretionary performance bonus, equity awards
and to participate in employee benefits plans as the Company may institute from time to time at the discretion of the Board.
On January 3, 2019, the
Company entered into a Letter Agreement with Dr. Jin, pursuant to which his annual base salary set forth in his employment agreement was
increased to $360,000, effective January 1, 2019. Pursuant to the agreement, Mr. Jin may be terminated for “cause” as defined
and Mr. Jin may resign for “good reason” as defined. In the event Mr. Jin is terminated without cause or resigns for good
reason, the Company will be required to pay Mr. Jin all accrued salary and bonuses, reimbursement for all business expenses and Mr. Jin’s
salary for one year. In the event Mr. Jin is terminated with cause, resigns without good reason, dies or is disabled, the Company will
be required to pay Mr. Jin all accrued salary and bonuses and reimbursement for all business expenses. Under the agreement Mr. Jin is
subject to confidentiality, non-compete and non-solicitation restrictions. This agreement has not been extended, however Dr. Jin is continuing
his employment with the Company at will and otherwise under the same terms and conditions, except that Dr. Jin agreed to a salary reduction
as set forth in the table above for the year ended December 31, 2023 as part of the Company’s cost reduction measures.
Luisa Ingargiola
On February 21, 2017,
Ms. Ingargiola and the Company entered into an Executive Retention Agreement effective February 9, 2017, pursuant to which Ms. Ingargiola
agreed to serve as Chief Financial Officer in consideration of an annual salary. On January 3, 2019, the Company entered into a Letter
Agreement with Ms. Ingargiola, pursuant to which her annual base salary set forth in her employment agreement was increased to $350,000
effective January 1, 2019.
The
employment of Ms. Ingargiola is at will and may be terminated at any time, with or without formal cause. Pursuant to the terms of Executive
Retention Agreement with Ms. Ingargiola, the Company has agreed to provide specified severance and bonus amounts and to accelerate the
vesting on her equity awards upon termination upon a change of control or an involuntary termination, as each term is defined in the
agreements.
In
the event of a termination upon a change of control, Ms. Ingargiola is entitled to receive an amount equal to 12 months of her base salary
and the target bonus then in effect for the executive officer for the year in which such termination occurs, such bonus payment to be
pro-rated to reflect the full number of months the executive remained in the Company’s employ. In addition, the vesting on any
stock option held by the executive officer will be accelerated in full. At the election of the executive officer, the Company will also
continue to provide health related employee insurance coverage for twelve months, at the Company’s expense.
In
the event of an involuntary termination, Ms. Ingargiola is entitled to receive an amount equal to six months of her base salary and the
target bonus then in effect for the executive officer for the six months in which such termination occurs, such bonus payment to be pro-rated
to reflect the full number of months the executive remained in the Company’s employ. Such payment will be increased to 12 months
upon the one-year anniversary of the retention agreement. In addition, the vesting on any stock option held by the executive officer
will be accelerated in full. At the election of the executive officer, the Company will also continue to provide health related employee
insurance coverage for twelve months, at the Company’s expense.
Meng
Li
On
January 11, 2017, Avalon Shanghai entered into an Executive Employment Agreement with Meng Li, the Company’s COO and Secretary.
Pursuant to the agreement, Ms. Li was employed as Chief Operating Officer and President of Avalon Shanghai initially through November
30, 2019, unless earlier terminated pursuant to the terms of the agreement. On February 20, 2020, the Company entered into a Letter Agreement
with Meng Li pursuant to which the term of Ms. Li’s Executive Employment Agreement entered between the Company’s subsidiary
and Ms. Li dated January 11, 2017 was extended an additional three years.
During
the term of the agreement, Ms. Li is entitled to a base salary and will be eligible for a discretionary performance bonus, equity awards
and to participate in employee benefits plans as the Avalon Shanghai may institute from time to time at the discretion of its Board of
Directors. On January 3, 2019, the Company entered into a Letter Agreement with Ms. Li, pursuant to which her annual base salary set
forth in her employment agreement was increased to $340,000 effective January 1, 2019, except that Ms. Li agreed to a salary reduction
as set forth in the table above for the year ended December 31, 2023 as part of the Company’s cost reduction measures. Pursuant
to the agreement, Ms. Li may be terminated for “cause” as defined and Ms. Li may resign for “good reason” as
defined. In the event Ms. Li is terminated without cause or resigns for good reason, Avalon Shanghai will be required to pay Ms. Li all
accrued salary and bonuses, reimbursement for all business expenses and Ms. Li’s salary for one year. In the event Ms. Li is terminated
with cause, resigns without good reason, dies or is disabled, Avalon Shanghai will be required to pay Ms. Li all accrued salary and bonuses
and reimbursement for all business expenses. Under the agreement Ms. Li is subject to confidentiality, non-compete and non-solicitation
restrictions.
Option
Exercises and Stock Vested
There
were no options exercised by our executive officers or stock vested to our executive officers during the year ended December 31, 2023.
Outstanding
Equity Awards at Fiscal Year End
The
following table sets forth information with respect to the outstanding equity awards of our principal executive officers and principal
financial officer during 2023, and each person who served as an executive officer of the Company as of December 31, 2023:
| |
Outstanding
Equity Awards | |
| |
Option
Awards | |
Stock
Awards | |
Name
and principal position | |
Number
of securities underlying unexercised options
Exercisable (#) | |
Number
of securities underlying unexercised
options Unexercisable (#) | | |
Equity
incentive plan awards: Number of securities underlying unexercised options (#) | | |
Options
exercise price ($) | | |
Option
expiration Date | |
Number of
shares or units of stock
that have not vested (#) | | |
Market
value of shares or units of
stock that have not vested ($) | | |
Equity
incentive plan awards: Number of
unearned shares, units or other rights that have not vested (#) | | |
Equity
incentive plan awards: Market or payout value of unearned shares, units or other rights
that have not vested ($) | |
Luisa
Ingargiola, | |
200,000 | |
| - | | |
| 200,000 | | |
| 5.0 | | |
2/8/2027 | |
| - | | |
| - | | |
| - | | |
| - | |
CFO | |
40,000 | |
| - | | |
| 40,000 | | |
| 15.2 | | |
2/18/2030 | |
| - | | |
| - | | |
| - | | |
| - | |
David
Jin, | |
15,000 | |
| - | | |
| 15,000 | | |
| 20.0 | | |
1/2/2024 | |
| - | | |
| - | | |
| - | | |
| - | |
CEO | |
40,000 | |
| - | | |
| 40,000 | | |
| 15.2 | | |
2/18/2030 | |
| - | | |
| - | | |
| - | | |
| - | |
Meng
Li, | |
15,000 | |
| - | | |
| 15,000 | | |
| 20.0 | | |
1/2/2024 | |
| - | | |
| - | | |
| - | | |
| - | |
COO | |
30,000 | |
| - | | |
| 30,000 | | |
| 15.2 | | |
2/18/2030 | |
| - | | |
| - | | |
| - | | |
| - | |
No
Pension Benefits
The
Company does not maintain any plan that provides for payments or other benefits to its executive officers at, following or in connection
with retirement and including, without limitation, any tax-qualified defined benefit plans or supplemental executive retirement plans.
No
Nonqualified Deferred Compensation
The
Company does not maintain any defined contribution or other plan that provides for the deferral of compensation on a basis that is not
tax-qualified.
Pay
Versus Performance
Pay
Versus Performance Table
In
accordance with rules adopted by the SEC pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the “Dodd-Frank
Act,” below is disclosure regarding executive compensation for our principal executive officer (“PEO,” also known as
our CEO), and other Named Executive Officers and company financial performance for the fiscal years listed below. The Compensation Committee
did not consider the pay versus performance disclosure below in making its pay decisions for any of the years shown. Pursuant to SEC
rules, the information in this “Pay Versus Performance” section shall not be deemed to be incorporated by reference
into any Avalon GloboCare Corp. filing under the Securities Act or Exchange Act, unless expressly incorporated by specific reference
in such filing.
Year | |
Summary Compensation Table Total for PEO ($) (1) | | |
Compensation Actually Paid to PEO ($) | | |
Average Summary Compensation Table Total for Non-PEO NEOs ($) (1) | | |
Average Compensation Actually Paid to Non-PEO NEOs ($) | | |
Value of Initial Fixed $100 Investment Based on Total Shareholder Return ($)(2) | | |
Net Loss ($) | |
2023 | |
| 330,000 | | |
| 330,000 | | |
| 315,122 | | |
| 315,122 | | |
| 64 | | |
| (16,707,010 | ) |
2022 | |
| 360,000 | | |
| 360,000 | | |
| 345,000 | | |
| 345,000 | | |
| 63 | | |
| (11,930,847 | ) |
(1) |
Our PEO for 2023 and 2022 was David Jin, our current Chief Executive Officer and President. Our Other Named Executive Officers for 2023 and 2022 were Luisa Ingargiola, our Chief Financial Officer, and Meng Li, our Chief Operating Officer. |
(2) |
Total Shareholder Return (“TSR”) illustrates the value, as of the last day of the indicated fiscal year, of an investment of $100 in our common stock on December 31, 2021. |
Pay
Versus Performance Relationships Descriptions
Relationship
between “Compensation Actually Paid” and TSR
There
is a limited relationship between TSR and our PEO and Named Executive Officers “compensation actually paid.” This is primarily
because “compensation actually paid” is principally driven by fixed cash compensation. In addition, for the periods reported
in the table, we did not use TSR as a measure of our performance in any of our executive compensation plans.
Relationship
between “Compensation Actually Paid” and Net Loss
There
is a limited relationship between net loss and our PEO and Named Executive Officers “compensation actually paid.” This is
primarily because “compensation actually paid” is principally driven by fixed cash amount. In addition, for the periods reported
in the table, we did not use net loss as a measure of our performance in any of our executive compensation plans.
DIRECTOR
COMPENSATION
2023
Director Compensation Table
The
following table sets forth information concerning the compensation earned or paid to certain of our non-employee directors during the
fiscal year ended December 31, 2023:
Name | |
Fees Earned or Paid in Cash $ | | |
Stock Awards $ | | |
Option Awards $ | | |
Non-equity Incentive Plan Compensation
$ | | |
Change in Pension Value and Non- Qualified
Deferred Compensation Earnings $ | | |
All Other Compensation $ | | |
Total $ | |
Wilbert Tauzin (1) | |
| - | | |
| - | | |
| 38,052 | | |
| - | | |
| - | | |
| - | | |
| 38,052 | |
Wenzhao Lu | |
| 100,000 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 100,000 | |
David Jin | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Lourdes Felix (2) | |
| 68,488 | | |
| - | | |
| 23,268 | | |
| - | | |
| - | | |
| - | | |
| 91,756 | |
Steven Sanders (3) | |
| 70,000 | | |
| - | | |
| 33,665 | | |
| - | | |
| - | | |
| - | | |
| 103,665 | |
Tevi Troy (4) | |
| 60,000 | | |
| - | | |
| 33,665 | | |
| - | | |
| - | | |
| - | | |
| 93,665 | |
William Stilley (5) | |
| 70,000 | | |
| - | | |
| 33,665 | | |
| - | | |
| - | | |
| - | | |
| 103,665 | |
(1) | Mr.
Tauzin’s 2023 compensation consisted of 20,000 options vested and valued at $38,052. |
(2) | Ms.
Felix’s 2023 compensation consisted of cash of $68,488 and 7,803 stock options vested and valued at $23,268. |
(3) | Mr.
Sanders’s 2023 compensation consisted of cash of $70,000 and 8,000 options vested and valued at $33,665. |
(4) | Dr.
Troy’s 2023 compensation consisted of cash of $60,000 and 8,000 options vested and valued at $33,665. |
(5) | Mr.
Stilley’s 2023 compensation consisted of cash of $70,000 and 8,000 options vested and valued at $33,665. |
REPORT
OF THE AUDIT COMMITTEE*
The
undersigned members of the Audit Committee of the Board of Directors of Avalon GloboCare Corp. (the “Company”) submit this
report in connection with the Audit Committee’s review of the financial reports for the fiscal year ended December 31, 2023 as
follows:
1. | The
Audit Committee has reviewed and discussed with management the audited financial statements for the Company for the fiscal year ended
December 31, 2023. |
2. | The Audit Committee has
discussed with representatives of Marcum LLP, the Company’s former independent public accounting firm, the matters required to
be discussed by the applicable requirements of the Public Company Accounting Oversight Board (the “PCAOB”) and the
Securities and Exchange Commission (“SEC”). |
3. | The Audit Committee has
discussed with Marcum LLP, the Company’s former independent public accounting firm, the auditors’ independence from
management and the Company has received the written disclosures and the letter from the independent auditors required by applicable
requirements of the PCAOB. |
In
addition, the Audit Committee considered whether the provision of non-audit services by Marcum LLP was compatible with maintaining its
independence. In reliance on the reviews and discussions referred to above, the Audit Committee recommended to the Board of Directors
of the Company (and the Board of Directors of the Company has approved) that the audited financial statements be included in our Annual
Report on Form 10-K for the fiscal year ended December 31, 2023 for filing with the SEC.
|
Audit Committee of Avalon GloboCare Corp. |
|
|
|
William Stilley |
|
Tevi Troy |
|
Steven Sanders |
* | The
foregoing report of the Audit Committee is not to be deemed “soliciting material” or deemed to be “filed” with
the SEC (irrespective of any general incorporation language in any document filed with the SEC) or subject to Regulation 14A of the Securities
Exchange Act of 1934, as amended (“Exchange Act”), or to the liabilities of Section 18 of the Exchange Act, except to the
extent we specifically incorporate it by reference into a document filed with the SEC. |
On July 10, 2024, the Audit Committee of the Board
of Directors discharged Marcum LLP (“Marcum”), the Company’s former independent registered public accounting firm. On
July 10, 2024, the Audit Committee appointed M&K as the Company’s new independent registered accounting firm.
Equity
Compensation Plan Information
Equity
Compensation Plan Information
Amended
and Restated 2020 Stock Incentive Plan
On
August 29, 2023, the Board adopted the Avalon GloboCare Corp. Amended and Restated 2020 Stock Incentive Plan (the “Amended and
Restated 2020 Plan”), subject to stockholder approval, which was received on December 19, 2023. The Amended and Restated 2020 Plan
provides for the grant of incentive stock options that are intended to qualify under Section 422 of the Code (“ISOs”), nonstatutory
stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance-based stock awards and performance-based
cash awards. ISOs may be granted only to employees. All other awards may be granted to employees, including officers, and to the Company’s
non-employee directors, consultants and other advisors.
A
total of 2,000,000 shares of our common stock were initially available under the Amended and Restated 2020 Plan. In addition, the number
of shares of our common stock reserved for issuance under the Amended and Restated 2020 Plan automatically increases on January 1 of
each year, beginning on January 1, 2024, by 1% of the total number of shares of our common stock outstanding on December 31 of the preceding
calendar year, or a lesser number of shares determined by our Board. On January 1, 2024, the number of shares of our common stock reserved
for issuance under the Amended and Restated 2020 Plan was increased by an aggregate of 109,995 shares. As of the Record
Date, a total of [●] shares of our common stock are available for issuance under the Amended and Restated 2020 Plan, including
shares that are the subject of outstanding awards as of such date.
Clawback/Recoupment. Awards
granted under the Amended and Restated 2020 Plan will be subject to the requirement that the awards be forfeited or amounts repaid to
the Company after they have been distributed to the participant (i) to the extent set forth in an award agreement or (ii) to the extent
covered by any clawback or recapture policy adopted by the Company from time to time (including the Clawback Policy adopted by the Board
on November 16, 2023), or any applicable laws that impose mandatory forfeiture or recoupment, under circumstances set forth in such applicable
laws.
Amendment,
Termination. Our Board may at any time amend, suspend or terminate the Amended and Restated 2020 Plan for the purpose of
satisfying the requirements of the Code, or other applicable law or regulation or for any other legal purpose, provided that, without
the consent of our stockholders, the Board may not (i) increase the number of shares of our common stock available under the Amended
and Restated 2020 Plan, (ii) change the group of individuals eligible to receive awards, or (iii) extend the term of the Amended and
Restated 2020 Plan.
2020
Incentive Stock Plan
On
June 12, 2020, the Board adopted the Avalon GloboCare Corp. 2020 Incentive Stock Plan (the “2020 Plan”), subject to stockholder
approval, which was received on August 4, 2020.
The
general purpose of the 2020 Plan is to provide a means whereby eligible directors, officers, employees or consultants to the Company
develop a sense of proprietorship and personal involvement in our development and financial success, and to encourage them to devote
their best efforts to our business, thereby advancing our interests and the interests of our stockholders. We believe that the 2020 Plan
advances the Company’s interests by enhancing our ability to (i) attract, retain and reward employees, officers, directors and
consultants who are in a position to make significant contributions to our success; (ii) encourage our employees, officers, directors
and consultants to take into account our long-term interests through ownership of our shares of our common stock; and (iii) to provide
incentives for such persons to exert maximum efforts for our success.
The
Board has reserved 500,000 shares of our common stock for issuance under the 2020 Plan, subject to customary adjustments for stock splits,
stock dividends or similar transactions. Under the 2020 Plan, awards may be made in the form of options to purchase shares of our common
stock, as well as restricted shares of our common stock and restricted stock units payable in shares of our common stock. Options may
be granted which are intended to qualify as ISOs under Section 422 of the Code or which are not intended to qualify as ISOs thereunder.
However, ISOs may only be granted to employees. If any option granted under the 2020 Plan terminates without having been exercised in
full or if any award is forfeited, or if shares otherwise issuable are withheld to satisfy tax withholding obligations, the number of
shares of our common stock as to which such option or award was forfeited or withheld will be available for future grants under the 2020
Plan.
The
2020 Plan is not a qualified deferred compensation plan under Section 401(a) of the Code and is not subject to the provisions of the
Employee Retirement Income Security Act of 1974.
2019
Incentive Stock Plan
On
June 7, 2019, the Board adopted the Avalon GloboCare Corp. 2019 Incentive Stock Plan (the “2019 Plan”), subject to stockholder
approval, which was received on August 6, 2019. There are 500,000 shares of our common stock reserved for issuance under the 2019 Plan,
subject to customary adjustments for stock splits, stock dividends or similar transactions. As of the Record Date, [●] shares remained
available for issuance under the 2019 Plan.
The
following table provides information with respect to our 2019 Plan, 2020 Plan, and Amended and Restated 2020 Plan under which equity
compensation was authorized as of December 31, 2023:
Plan category | |
Number of securities to be issued upon
exercise of outstanding options, warrants and rights (a) | | |
Weighted average exercise price of
outstanding options, warrants and rights (b) | | |
Number of securities remaining available
for future issuance under the 2019 Plan and 2020 Plan (excluding securities reflected
in column (a)) (c) | |
Equity compensation plan approved by security holders | |
| | |
| | |
| |
Amended and Restated 2020 Plan (4) | |
| — | | |
| — | | |
| | |
2020 Plan | |
| 372,403 | (1) | |
$ | 4.94 | (2) | |
| 127,597 | |
2019 Plan | |
| 406,800 | (3) | |
$ | 18.36 | (2) | |
| 93,200 | |
Equity compensation plans not approved by security holders | |
| — | | |
| — | | |
| — | |
Total | |
| 779,203 | | |
$ | 12.36 | | |
| 220,797 | |
(1) | Includes
324,803 shares of our common stock issuable upon exercise of outstanding options and 47,600 shares of our common stock issuable pursuant
to outstanding restricted stock units. |
(2) | The
weighted average exercise price does not take into account the shares issuable pursuant to outstanding restricted stock units, which
have no exercise price. |
(3) | Includes
402,000 shares of our common stock issuable upon exercise of outstanding options and 4,800 shares of our common stock issuable pursuant
to outstanding restricted stock units. |
(4) | No
issuances have been made as of December 31, 2023 under the Amended and Restated 2020 Plan. |
Security
Ownership of Certain Beneficial Owners and Management
Beneficial
ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities.
In accordance with SEC rules, shares of our common stock which may be acquired upon exercise of stock options or warrants which are currently
exercisable or which become exercisable within 60 days of the date of the applicable table below are deemed beneficially owned by the
holders of such options and warrants and are deemed outstanding for the purpose of computing the percentage of ownership of such person,
but are not treated as outstanding for the purpose of computing the percentage of ownership of any other person. Subject to community
property laws, where applicable, the persons or entities named in the tables below have sole voting and investment power with respect
to all shares of our common stock indicated as beneficially owned by them.
The
following table sets forth certain information as of the Record Date with respect to the beneficial ownership of the outstanding common
stock by:
| ● | Any
holder of more than 5%; |
| ● | Each
of our named executive officers and directors; and |
| ● | Our
directors and executive officers as a group. |
Except
as otherwise indicated, each of the stockholders listed below has sole voting and investment power over the shares beneficially owned.
Name of Beneficial Owner (1) |
|
Common
Stock
Beneficially
Owned |
|
|
Percentage
of Common
Stock (2) |
|
Named executive officers and directors: |
|
|
|
|
|
|
Wenzhao Lu (3) |
|
3,583,788 |
|
|
30.8 |
% |
David Jin, MD, PhD (4) |
|
|
1,585,000 |
|
|
|
13.6 |
% |
Meng Li (5) |
|
|
545,000 |
|
|
|
4.7 |
% |
Luisa Ingargiola (6) |
|
|
240,000 |
|
|
|
2.0 |
% |
Steven A. Sanders (7) |
|
|
38,000 |
|
|
|
* |
|
Wilbert J. Tauzin II (8) |
|
|
64,000 |
|
|
|
* |
|
William B. Stilley III (9) |
|
|
38,000 |
|
|
|
* |
|
Tevi Troy (10) |
|
|
38,000 |
|
|
|
* |
|
Lourdes Felix* (11) |
|
|
13,803 |
|
|
|
* |
|
All officers and directors as a group (9 persons) |
|
|
6,145,591 |
|
|
|
52.6 |
% |
Other 5% stockholders: |
|
|
|
|
|
|
|
|
Mast Hill, L.P. |
|
|
3,881,152 |
|
|
|
33.3 |
% |
| (1) | Except
as otherwise indicated, the address of each beneficial owner is c/o Avalon GloboCare Corp., 4400 Route 9 South, Suite 3100, Freehold,
New Jersey 07728. |
| (2) | Applicable
percentage ownership is based on [●] shares of our common stock outstanding as of the
Record Date, together with securities exercisable or convertible into shares of our common
stock within 60 days of the Record Date for each stockholder. Beneficial ownership is determined
in accordance with the rules of the SEC and generally includes voting or investment power
with respect to securities. Shares of common stock that are currently exercisable or exercisable
within 60 days of the Record Date are deemed to be beneficially owned by the person holding
such securities for the purpose of computing the percentage of ownership of such person,
but are not treated as outstanding for the purpose of computing the percentage ownership
of any other person. |
| (3) | Wenzhao
Lu holds 3,583,788 shares of our common stock. |
| (4) | David
Jin holds (i) 1,545,000 shares of our common stock and (ii) 40,000 vested options to acquire
40,000 shares of our common stock. |
| (5) | Meng
Li holds (i) 515,000 shares of our common stock and (ii) 30,000 vested options to acquire
30,000 shares of our common stock. |
| (6) | Represents
240,000 vested options to acquire 240,000 shares of our common stock. |
(7) |
Represents
stock option to acquire 38,000 shares of our common stock, 36,000 of which have been vested and 2,000 of which will be vested within
60 days of the Record Date. |
(8) |
Represents
stock option to acquire 64,000 shares of our common stock, 63,000 of which have been vested and 1,000 of which will be vested
within 60 days of the Record Date. |
(9) |
Represents
stock option to acquire 38,000 shares of our common stock, 36,000 of which have been vested and 2,000 of which will be vested within
60 days of the Record Date. |
(10) |
Represents
stock option to acquire 38,000 shares of our common stock, 36,000 of which have been vested and 2,000 of which will be vested within
60 days of the Record Date. |
(11) |
Represents
stock option to acquire 13,803 shares of our common stock, 11,803 of which have been vested and 2,000 of which will be vested within
60 days of the Record Date. |
(12) |
Represents
principal and accrued and unpaid interest, convertible into 3,881,152 shares of our common stock at a conversion price of $0.75 per
share. |
Transactions
with Related Persons
Other
than compensation arrangements for our named executive officers and directors, we describe below each transaction or series of similar
transactions, since January 1, 2022 to which we were a party or will be a party, in which:
| ● | The
amounts involved exceeded or will exceed the lesser of (i) $120,000 or (ii) 1% of the average
total assets of the Company at year end for the last two completed fiscal years; and |
| ● | Any
of our directors, executive officers, promoters or holders of more than 5% of our capital
stock, or any member of the immediate family of the foregoing persons, had or will have a
direct or indirect material interest. |
Compensation
arrangements for our named executive officers and directors are described in the section entitled “Executive Compensation.”
Rental
Revenue from Related Party and Rent Receivable – Related Party
The
Company leases part of its commercial real property located in New Jersey to D.P. Capital Investments LLC, a company controlled
by Wenzhao Lu, the Company’s largest shareholder and chairman of the Board. The term of the related party lease agreement is five
years commencing on May 1, 2021 and will expire on April 30, 2026.
For
both the years ended December 31, 2023 and 2022, the related party rental revenue amounted to $50,400 and has been included in rental
revenue on the accompanying consolidated statements of operations and comprehensive loss.
At
December 31, 2023 and 2022, the related party rent receivable totaled $124,500 and $74,100, respectively, which has been included
in rent receivable on the accompanying consolidated balance sheets, and no allowance for doubtful accounts was deemed to be required
on the receivable.
Services
Provided by Related Party
From
time to time, Wilbert Tauzin, a director of the Company, and his son provide consulting services to the Company. As compensation
for professional services provided, the Company recognized consulting expenses of $86,528 and $144,064 for the years ended
December 31, 2023 and 2022, respectively, which have been included in professional fees on the accompanying consolidated statements of
operations and comprehensive loss.
Accrued
Liabilities and Other Payables – Related Parties
In
2017, the Company acquired Beijing Genexosome for a cash payment of $450,000. As of December 31, 2023 and 2022, the unpaid acquisition
consideration of $100,000, was payable to Dr. Yu Zhou, a former director and former co-chief executive officer and 40% owner of
Genexosome, and has been included in accrued liabilities and other payables — related parties on the accompanying consolidated
balance sheets.
During
the period from June 2023 through December 2023, Lab Services MSO paid shared expense on behalf of the Company. As of December 31,
2023, the balance due to Lab Services MSO amounted to $72,746, which has been included in accrued liabilities and other payables —
related parties on the accompanying consolidated balance sheets.
As
of December 31, 2023 and 2022, $33,712 and $0 of accrued and unpaid interest related to borrowings from Wenzhao Lu, the Company’s
largest shareholder and Chairman of the Board, respectively, have been included in accrued liabilities and other payables — related
parties on the accompanying consolidated balance sheets.
Borrowings
from Related Party
Line
of Credit
On
August 29, 2019, the Company entered into a Line of Credit Agreement (the “Line of Credit Agreement”) providing the Company
with a $20 million line of credit (the “Line of Credit”) from Wenzhao Lu (the “Lender”), the largest shareholder
and Chairman of the Board. The Line of Credit allows the Company to request loans thereunder and to use the proceeds of such loans for
working capital and operating expense purposes until the facility matures on December 31, 2024. The loans are unsecured and are
not convertible into equity of the Company. Loans drawn under the Line of Credit bear interest at an annual rate of 5% and each
individual loan is payable three years from the date of issuance. The Company has a right to draw down on the Line of Credit and such
right is not at the discretion of the related party Lender. The Company may, at its option, prepay any borrowings under the Line of Credit,
in whole or in part at any time prior to maturity, without premium or penalty. The Line of Credit Agreement includes customary events
of default. If any such event of default occurs, the Lender may declare all outstanding loans under the Line of Credit to be due and
payable immediately.
In
the years ended December 31, 2023 and 2022, activity recorded for the Line of Credit is summarized in the following table:
Outstanding principal under the Line of Credit at January 1, 2022 | |
$ | 2,750,262 | |
Draw down from Line of Credit | |
| 100,000 | |
Repayment of Line of Credit | |
| (410,000 | ) |
Settlement of Line of Credit in shares | |
| (2,440,262 | ) |
Outstanding principal under the Line of Credit at December 31, 2022 | |
| - | |
Draw down from Line of Credit | |
| 850,000 | |
Outstanding principal under the Line of Credit at December 31, 2023 | |
$ | 850,000 | |
For
the years ended December 31, 2023 and 2022, the interest expense related to related party borrowings amounted to $33,712 and $79,898,
respectively, and has been reflected as interest expense — related party on the accompanying consolidated statements of operations
and comprehensive loss.
As
of December 31, 2023 and 2022, the related accrued and unpaid interest for the Line of Credit was $33,712 and $0, respectively,
and has been included in accrued liabilities and other payables — related parties on the accompanying consolidated balance sheets.
As
of December 31, 2023, the Company used approximately $6.8 million of the credit facility and has approximately $13.2 million
remaining available under the Line of Credit.
Common Stock Sold
to Related Party for Cash
On
August 5, 2022, the Company sold 44,872 shares of its common stock at a purchase price of $7.8 per share, the fair market
value on the transaction date, to Wenzhao Lu, the Chairman of the Board, pursuant to a subscription agreement. The Company received proceeds
of $350,000 (See Note 14 – Common Shares Sold for Cash).
Series
A Preferred Stock Sold to Related Party for Cash
On
December 14, 2022, the Company entered into a Securities Purchase Agreement with Wenzhao Lu, the Company’s Chairman of the Board,
pursuant to which the Company sold to Mr. Lu 4,000 shares of its Series A Preferred Stock, stated value $1,000, for gross proceeds
of $4,000,000 (See Note 14 – Series A Preferred Stock Sold for Cash).
Membership
Interest Purchase Agreement
On
November 17, 2023, the Company entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with Wenzhao
Lu (the “Purchaser”), the largest shareholder and Chairman of the Board, pursuant to which (i) the Purchaser will acquire
from the Company 30% of the total outstanding membership interests of Avalon RT 9, a wholly owned subsidiary of the Company for a cash
purchase price of $3,000,000 (the “Acquisition”), and (ii) for a period of twelve months following the closing of the Acquisition,
the Purchaser shall have the option to purchase from the Company up to an additional 70% of the outstanding membership interests of Avalon
RT 9 for a purchase price of up to $7,000,000 (the “Option”), subject to the terms and conditions of a membership interest
purchase agreement to be negotiated and entered into between the Purchaser and the Company at such time that the Purchaser desires to
exercise the Option. The Acquisition was not closed as of December 31, 2023. The Company received $485,714 from Wenzhao Lu as of December
31, 2023, which was recorded as advance from sale of noncontrolling interest – related party on the accompanying consolidated balance
sheets.
Policies
and Procedures for Related Party Transactions
Our
Board has adopted a policy that our executive officers, directors, nominees for election as a director, beneficial owners of more than
5% of any class of our common stock, any members of the immediate family of any of the foregoing persons and any firms, corporations
or other entities in which any of the foregoing persons is employed or is a partner or principal or in a similar position or in which
such person has a 5% or greater beneficial ownership interest, are not permitted to enter into a transaction with us without the prior
consent of our Board acting through the Audit Committee or, in certain circumstances, the Chairman of the Audit Committee. Any request
for us to enter into a transaction with a related party, in which the amount involved exceeds $100,000 and such related party would have
a direct or indirect interest must first be presented to our Audit Committee, or in certain circumstances the Chairman of our Audit Committee,
for review, consideration and approval. In approving or rejecting any such proposal, our Audit Committee, or the Chairman of our Audit
Committee, is to consider the material facts of the transaction, including, but not limited to, whether the transaction is on terms no
less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances, the extent of the
benefits to us, the availability of other sources of comparable products or services and the extent of the related party’s interest
in the transaction.
Director
Independence
Our
Board undertook a review of its composition, the composition of its committees and the independence of each of its directors. Based upon
information requested from and provided by each director concerning his or her background, employment and affiliations, including family
relationships, our Board has determined that Steven A. Sanders, Lourdes Felix, William B. Stilley, III, and Tevi Troy do not have a relationship
that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these
directors is “independent” as that term is defined under Nasdaq and SEC rules.
PROPOSAL
NO. 2: RATIFY THE APPOINTMENT OF M&K AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31,
2024
On July 10, 2024, the Audit Committee of the Board of Directors discharged
Marcum, the Company’s former independent registered public accounting firm. On July 10, 2024, the Audit Committee appointed M&K
as the Company’s new independent registered accounting firm to audit our financial statements for the
fiscal year ending December 31, 2024, and has further directed that management submit their selection of independent registered public
accounting firm for ratification by our stockholders at the Annual Meeting. Neither M&K nor any of its members has any direct or indirect
financial interest in or any connection with us in any capacity other than as public registered accounting firm.
Principal
Accountant Fees and Services
The
following table summarizes the fees paid for professional services rendered by Marcum, our independent registered public accounting firm,
for each of the last two fiscal years:
Fee Category | |
2023 | | |
2022 | |
Audit Fees | |
$ | 292,005 | | |
$ | 196,473 | |
Audit-Related Fees | |
$ | 198,158 | | |
$ | - | |
Tax Fees | |
$ | - | | |
$ | - | |
All Other Fees | |
$ | - | | |
$ | - | |
Total Fees | |
$ | 490,163 | | |
$ | 196,473 | |
M&K did not have
any fees in the fiscal years ended December 31, 2023 or 2022.
Audit
Fees
Consists
of fees billed for professional services rendered for the audit of our annual consolidated financial statements, review of our Annual
Report on Form 10-K, and review of the interim consolidated financial statements included in our Quarterly Reports on Form 10-Q, and
services that are normally provided by our independent auditors in connection with statutory and regulatory filings or engagements, including
registration statements.
Audit-Related
Fees
Consists
of fees billed for assurance and related services that are reasonably related to the performance of the audit and or review of our consolidated
financial statements and are not reported under “Audit Fees”, such as audits and reviews in connection with the acquisition
of Lab Services MSO.
Tax
Fees
Consists
of fees billed for professional services for tax compliance, tax advice and tax planning.
All
Other Fees
Consists
of fees for products and services other than the services reported above. There were no management consulting services provided in 2023
or 2022.
Pre-Approval
Policy and Procedures
The
current policy of the directors, acting as the Audit Committee, is to approve the appointment of the principal auditing firm and any
permissible audit-related services. The audit and audit related fees include fees for the annual audit of the financial statements and
review of financial statements included in Quarterly Reports on Form 10-Q. Fees charged by the auditor were approved by the Board with
engagement letters signed by the Audit Committee Chairman.
The
Audit Committee is responsible for the pre-approval of audit and permitted non-audit services to be performed by the Company’s
independent auditor. The Audit Committee will, on an annual basis, consider and, if appropriate, approve the provision of audit and non-audit
services by the auditor. Thereafter, the Audit Committee will, as necessary, consider and, if appropriate, approve the provision of additional
audit and non-audit services by the auditor which are not encompassed by the Audit Committee’s annual pre-approval and are not
prohibited by law. The Audit Committee has delegated to the Chair of the Audit Committee the authority to pre-approve, on a case-by-case
basis, non-audit services to be performed by the auditor. The Audit Committee has approved all audit and permitted non-audit services
performed by the auditor for the year ended December 31, 2023.
Attendance
at Annual Meeting
Representatives
of M&K are expected to be present at the Annual Meeting and will have an opportunity to make a statement if they so desire and will
be available to respond to appropriate questions from stockholders.
This proposal, to ratify the appointment of M&K
as our independent registered public accounting firm for the fiscal year ending December 31, 2024, requires the affirmative vote of a
majority of the total votes properly cast at the Annual Meeting, in person or by proxy. As a result, abstentions, if any, will not affect
the outcome of the vote on this proposal. Approval of Proposal No. 2 is not conditioned upon approval of any other proposal.
THE
BOARD RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” THE RATIFICATION OF M&K AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM.
PROPOSAL
NO. 3: APPROVAL OF THE POTENTIAL ISSUANCE OF SHARES OF COMMON STOCK IN EXCESS OF 19.99% OF OUR OUTSTANDING COMMON STOCK
PURSUANT TO NASDAQ LISTING RULES
Our Board is seeking the approval of our stockholders
of the potential issuance of shares of our common stock to Mast Hill Fund, L.P. (“Mast Hill”) in excess of 19.99% of our outstanding
common stock pursuant to Nasdaq Listing Rules 5635(b), 5635(d) and 5635(e). In all instances, we may not issue shares of our common stock
to Mast Hill under the Securities Purchase Agreement (as hereinafter defined) if it would result in Mast Hill beneficially owning more
than 4.99% of our common stock, as set forth in the Securities Purchase Agreement.
Mast Hill Securities Purchase Agreement
As previously disclosed,
on June 5, 2024, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Mast
Hill for the issuance of 13% senior secured promissory notes in the aggregate principal amount of $2,845,000 (collectively, the “Notes”)
convertible into shares of the Company’s common stock, as well as the issuance of up to 402,000 shares of common stock as a commitment
fee and warrants for the purchase of up to 2,200,000 shares of common stock (the “Convertible Note Financing”). The Company
and its subsidiaries also entered into those certain security agreements (the “Security Agreements”), creating a security
interest in certain property of the Company and its subsidiaries to secure the prompt payment, performance and discharge in full of all
of the Company’s obligations under the Notes. The transaction closed on June 5, 2024 (the “Closing Date”).
Mast Hill acquired
the Notes in the principal amount of $2,845,000 and paid the purchase price of $2,702,750, after an original issue discount of $142,250,
with a conversion price of $0.75, subject to adjustment as provided in Notes. On the Closing Date, the Company issued to Mast Hill (i)
a warrant to purchase 1,000,000 shares of common stock with an exercise price of $0.65, exercisable until the five-year anniversary of
the Closing Date (the “First Warrant”), (ii) a warrant to purchase 1,200,000 shares of common stock with an exercise price
of $0.50, exercisable until the five-year anniversary of the Closing Date, which warrant will be cancelled and extinguished against payment
of the Notes (the “Second Warrant” and together with the First Warrant, the “Warrants”), and (iii) 402,000 shares
of common stock as additional consideration for the purchase of the Note ( the “Commitment Shares”), which were earned in
full as of the Closing Date. On the Closing Date, the Company delivered such duly executed Notes, Warrants and shares of common stock
to Mast Hill against delivery of such purchase price.
The Company received net cash amount of $881,210 from the Convertible
Note Financing after using the proceeds to pay off all previously issued convertible notes to Mast Hill of $1,206,867 and FirstFire of
$454,673, respectively, and to pay finder’s fee of $120,000 and lender’s costs of $40,000 related to this financing.
In all instances, we
may not issue shares of our common stock to Mast Hill under the Securities Purchase Agreement if it would result in Mast Hill beneficially
owning more than 4.99% of our common stock, as set forth in the Securities Purchase Agreement.
Reasons for this Proposal No. 3
Our common stock is listed on the Nasdaq Capital
Market and, as such, we are subject to the Nasdaq Listing Rules. We are seeking stockholder approval of the potential issuance of shares
of our common stock to Mast Hill in excess of 19.99% of our outstanding common stock in order to comply with Nasdaq Listing Rule 5635.
Nasdaq Listing Rule 5635(d) requires
stockholder approval of transactions other than a public offering involving the sale or issuance by the issuer of common stock (or securities
convertible into or exercisable for common stock) equal to 20% or more of the common stock or 20% or more of the voting power outstanding
before the issuance for a price that is less than the lower of: (i) the closing price of the common stock immediately preceding the
signing of the binding agreement for the issuance of such securities; or (ii) the average closing price of the common stock for the
five trading days immediately preceding the signing of the binding agreement for the issuance of such securities. Based upon
Nasdaq Listing Rule 5635(d), the number of shares of the Company’s common stock that may be issued pursuant to the Securities
Purchase Agreement (including the Commitment Shares), upon conversion of the Warrants, and upon conversion of the Notes, is subject to
an exchange cap (the “Exchange Cap”) of 19.99% of the outstanding number of shares of the Company’s common stock, unless
stockholder approval to exceed the Exchange Cap is approved. In all instances, we may not issue shares of our common stock to Mast Hill
under the Securities Purchase Agreement if it would result in Mast Hill beneficially owning more than 4.99% of our common stock, as set
forth in the Securities Purchase Agreement.
In addition, Nasdaq Listing Rule 5635(b) generally
requires us to obtain stockholder approval prior to the issuance of securities when the issuance or potential issuance will result in
a change of control. Pursuant to applicable Nasdaq guidance, a change of control may generally be deemed to occur when an investor would
own or have the right to acquire 20% or more of the outstanding shares of common stock or voting power and such ownership or voting power
would be the largest ownership position of the issuer. However, in determining if a change of control has occurred (and stockholder approval
is required), Nasdaq will consider all circumstances concerning the transaction and may determine that a change of control has occurred
even if the number of shares of common stock or voting power that an investor has a right to acquire is less than 20%.
If all of the Notes were converted to shares of our common stock, the
Warrants were exercised in full, and the Commitment Shares were issued, we would issue a number of shares of common stock that would exceed
the Exchange Cap. Therefore, we are asking stockholders to approve the issuance of more than 19.99% of our issued and outstanding common
stock pursuant to the Securities Purchase Agreement, including upon the conversion of the Notes and Warrants, and upon issuance of the
Commitment Shares. Effectively, we are seeking stockholder approval for the issuance of (i) up to an aggregate of 4,177,031 shares of
our common stock issuable pursuant to the Notes, which represents the number of shares of common stock we would be required to issue if
the Notes were converted in full at the floor price (including the maximum amount of accrued and unpaid interest), (ii) up to an aggregate
of 2,200,000 shares of our common stock issuable pursuant to the Warrants, which represents the number of shares of common stock we would
be required to issue if the Warrants were fully exercised, and (iii) 420,000 Commitment Shares which were issued on June 5, 2024. In all
instances, we may not issue shares of our common stock to Mast Hill under the Securities Purchase Agreement if it would result in Mast
Hill beneficially owning more than 4.99% of our common stock, as set forth in the Securities Purchase Agreement.
The Board is not seeking the approval of our stockholders to authorize
our entry into or consummation of the transactions contemplated by the Securities Purchase Agreement, as the offering has already been
completed, and the Notes, the Warrants and the Commitment Shares have already been issued. We are only asking for Nasdaq purposes for
approval of the issuance of (i) the Commitment Shares, (ii) up to 4,177,031 shares of our common stock upon conversion of the Notes, and
(iii) up to 2,200,000 shares of our common stock upon exercise of the Warrants.
Potential Consequences if Proposal No. 3 is
Not Approved
The failure of our stockholders to approve this
Proposal No. 3 will mean that: (i) we cannot permit the full conversion of the Notes and the Warrants, and (ii) we may incur
substantial additional costs and expenses. In addition, the Securities Purchase Agreement provides that it is an event of default if we
do not receive stockholder approval for the Proposal No. 3 as provided in the Securities Purchase Agreement, and therefore, our failure
to obtain such approval could result in a default under the Securities Purchase Agreement. Also, if, as a result of failing to obtain
stockholder approval, we are prohibited from issuing shares of common stock pursuant to exercise of the Warrant or conversion of the Notes
in excess of 19.99% of our outstanding common stock (or in an amount that would violate Nasdaq Listing Rule 5635(b)), we would likely
be required to seek alternative sources of financing, which may not be available on terms favorable to the Company, or at all.
Potential Adverse Effects of the Approval of
Proposal No. 3
If this Proposal No. 3 is approved, existing stockholders
will suffer dilution in their ownership interests in the future upon the issuance of the shares of common stock upon conversion of the
Notes, upon exercise of the Warrants, and upon issuance of the Commitment Shares. In addition, the sale into the public market of these
shares could materially and adversely affect the market price of our common stock.
Vote Required
Adoption of Proposal No. 3 requires an affirmative
vote of a majority of the outstanding common stock entitled to vote thereon. You may vote “FOR,” “AGAINST,” or
“ABSTAIN” from voting concerning Proposal No. 3. Abstentions will count toward the quorum and will have the same effect as
a vote against Proposal No. 3. Approval of Proposal No. 3 is not conditioned upon approval of any other proposal.
Recommendation
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS
THAT STOCKHOLDERS VOTE “FOR” APPROVAL OF THE POTENTIAL ISSUANCE OF SHARES OF COMMON STOCK IN EXCESS OF 19.99% OF OUR
OUTSTANDING COMMON STOCK PURSUANT TO NASDAQ LISTING RULES.
PROPOSAL
NO. 4: APPROVAL OF AMENDMENT TO CERTIFICATE OF INCORPORATION TO EFFECTUATE THE REVERSE STOCK SPLIT
On
November 3, 2023, we received written notice from Nasdaq that the closing bid price for the
Company’s common stock had been below $1.00 per share for the previous 30 consecutive business days, and that the Company was therefore
not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market as set forth in Nasdaq Listing
Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A),
the Company was provided a grace period of 180 calendar days, or until May 1, 2024, to regain compliance with the Minimum Bid Price Requirement.
On
May 2, 2024, the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to October 28,
2024, to regain compliance with the Minimum Bid Price Requirement. If at any time during this period the closing bid price of the Company’s
common stock is at least $1.00 per share for a minimum of 10 consecutive business days, the Nasdaq Staff will provide the Company with
written confirmation of compliance and the matter will be closed.
The
Company continues to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options,
including but not limited to, implementing the Reverse Stock Split to regain compliance with the Minimum Bid Price Requirement. If the
Company does not regain compliance within the allotted compliance period, Nasdaq will provide notice that the Company’s common
stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. There
can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement during this 180-day extension.
In response, and in an attempt to increase the
share price of our common stock, we are asking stockholders to adopt and approve an amendment to our Certificate of Incorporation (the
“Reverse Stock Split Amendment”) to effectuate the Reverse Stock Split of our issued and outstanding common stock. On [●],
2024, our Board unanimously approved and declared advisable the proposed Reverse Stock Split Amendment and recommends that our stockholders
adopt and approve the proposed Reverse Stock Split Amendment. If approved by stockholders, this Proposal No. 4 will authorize the amendment
of our Certificate of Incorporation to effectuate the Reverse Stock Split at a ratio of no less than 1-for-2 and no more than 1-for-15,
with such ratio to be determined at the sole discretion of the Board, with any fractional shares being rounded up to the next higher
whole share.
Assuming
stockholders approve the Reverse Stock Split Amendment, the effective date of the Reverse Stock Split will be determined at the sole
discretion of the Board and may occur as soon as the day of the Annual Meeting. The effective date of the Reverse Stock Split will be
publicly announced by us. The Board may determine, in its sole discretion, not to effectuate the Reverse Stock Split and not to file
any amendment to our Certificate of Incorporation.
If
we effectuate the Reverse Stock Split, then, except for adjustments that may result from the treatment of fractional shares as described
below, each stockholder will hold the same percentage of the then-outstanding shares of common stock immediately following the Reverse
Stock Split that such stockholder held immediately prior to the Reverse Stock Split. The par value of our common stock will remain unchanged
at $0.0001 per share. No fractional shares of common stock will be issued as a result of the Reverse Stock Split.
If the proposed Reverse Stock Split Amendment
is adopted and approved by our stockholders and the Board elects to effectuate the Reverse Stock Split, we will file an amendment to our
Certificate of Incorporation with the Delaware Secretary of State that sets forth the Reverse Stock Split Amendment and the Reverse Stock
Split ratio as determined by the Board. The Reverse Stock Split Amendment will be effective immediately upon filing with the Delaware
Secretary of State or such later time as is set forth therein. The Board also may determine in its discretion to abandon such an amendment,
and to not effectuate the Reverse Stock Split. The Board reserves the right to withdraw Proposal No. 4 relating to the Reverse Stock Split
and, if such proposal is withdrawn, all references in the Company’s proxy materials to voting for Proposal No. 4 should be disregarded.
Background
and Reasons for the Reverse Stock Split
Our
Board of Directors’ primary reason for approving and recommending the Reverse Stock Split is to increase the share price of our
common stock to a level that will enable the Company to comply with the Minimum Bid Requirement. The Board of Directors believes that
maintaining the Company’s Nasdaq listing is in the best interests of the Company and its stockholders. Among other things, the
Board of Directors believes that the Company’s Nasdaq listing may enable the Company to achieve better access to capital, encourage
investor interest and improve the marketability of our common stock to a broader range of investors. In addition, we believe the Reverse
Stock Split will make our common stock more attractive to a broader range of institutional and other investors, as we believe the current
market price of our common stock may affect its acceptability to certain institutional investors, professional investors, and other members
of the investing public. Many brokerage houses and institutional investors have internal policies and practices that either prohibit
them from investing in low-priced stocks or tend to discourage individual brokers from recommending low-priced stocks to their customers.
In addition, some of those policies and practices may function to make the processing of trades in low-priced stocks economically unattractive
to brokers. Moreover, because brokers’ commissions on low-priced stocks generally represent a higher percentage of the stock price
than commissions on higher-priced stocks, the current average price per share of our common stock can result in individual stockholders
paying transaction costs representing a higher percentage of their total share value than would be the case if the share price were substantially
higher. We believe that the Reverse Stock Split will make our common stock a more attractive and cost-effective investment for many investors,
which should enhance the liquidity available to the holders of our common stock. Accordingly, we believe that approval of the Reverse
Stock Split is in the Company’s and its stockholders’ best interests.
However,
despite approval of the Reverse Stock Split by our stockholders and the implementation thereof by our Board of Directors, there is no
assurance that the price of our common stock would be, or remain, following the Reverse Stock Split at a level high enough to enable
us to comply with the Minimum Bid Requirement or to attract capital investment in our company. There can be no assurance that the Company
will be able to regain compliance with the Minimum Bid Requirement, even if it maintains compliance with the other listing requirements.
Reducing
the number of outstanding shares of our common stock through the Reverse Stock Split is intended, absent other factors, to increase the
per share market price of our common stock. However, other factors, such as our financial results, general market conditions and the
market perception of our company, may adversely affect the market price of our common stock. As a result, there can be no assurance that
the Reverse Stock Split, if completed, will result in the intended benefits described above, that the market price of our common stock
will increase following the Reverse Stock Split or that the market price of our common stock will not decrease in the future. Additionally,
we cannot assure you that the market price per share of our common stock after the Reverse Stock Split will increase in proportion to
the reduction in the number of shares of our common stock outstanding before the Reverse Stock Split. Accordingly, the total market capitalization
of our common stock after the Reverse Stock Split may be lower than the total market capitalization before the Reverse Stock Split.
After undertaking a thorough analysis of the advisability
of the Reverse Stock Split and considering the totality of the circumstances, our Board of Directors believes that it is fair to the stockholders
of the Company, from a financial point of view, and in the best interests of us and our stockholders. The effectuation of the Reverse
Stock Split is conditioned on our Board’s consideration of the totality of the circumstances. The Board reserves the right to withdraw
Proposal No. 4 relating to the Reverse Stock Split and, if such proposal is withdrawn, all references in the Company’s proxy materials
to voting for Proposal No. 4 should be disregarded.
Board
Discretion to Implement the Reverse Stock Split
The Board believes that stockholder adoption and
approval of the Reverse Stock Split at a ratio of no less than 1-for-2 and no more than 1-for-15 is in the best interests of our stockholders
because it provides the Board and the Company with the flexibility to achieve the desired results of the Reverse Stock Split and because
it is not possible to predict market conditions at the time the Reverse Stock Split is implemented. If our stockholders approve Proposal
No. 4, the Board will implement the Reverse Stock Split only upon a determination that the Reverse Stock Split is in the best interests
of the stockholders at that time. The Board will then select the ratio for the Reverse Stock Split within the range approved by stockholders
that the Board determines to be advisable and in the best interests of the stockholders, considering relevant market conditions at the
time the Reverse Stock Split is to be implemented. The factors that the Board may consider in determining the Reverse Stock Split ratio
include, but are not limited to, the following:
| ● | The
historical and projected trading price and trading volume of our common stock; |
| ● | General
economic and other related conditions prevailing in our industry and in the marketplace;
and |
| ● | Our
ability to meet Nasdaq’s Minimum Bid Requirement. |
The
Board intends to select the Reverse Stock Split ratio that it believes will be most likely to achieve the anticipated benefits of the
Reverse Stock Split described above. The Reverse Stock Split is not intended as, and will not have the effect of, a “going private
transaction” covered by Rule 13e-3 under the Exchange Act. Following the implementation of the Reverse Stock Split, we will continue
to be subject to the periodic reporting requirements of the Exchange Act.
The Board reserves the right to withdraw Proposal
No. 4 relating to the Reverse Stock Split and, if such proposal is withdrawn, all references in the Company’s proxy materials to
voting for Proposal No. 4 should be disregarded.
Certain
Risks and Potential Disadvantages Associated with the Reverse Stock Split
We
cannot assure you that the proposed Reverse Stock Split will increase our common stock price. We expect that the Reverse Stock
Split will increase the per share trading price of our common stock. However, the effect of the Reverse Stock Split on the per share
trading price of our common stock cannot be predicted with any certainty, and the history of reverse stock splits for other companies
is varied. It is possible that the per share trading price of our common stock after the Reverse Stock Split will not increase in the
same proportion as the reduction in the number of our outstanding shares of common stock following the Reverse Stock Split. In addition,
although we believe the Reverse Stock Split may enhance the marketability of our common stock to certain potential investors, we cannot
assure you that, if implemented, our common stock will be more attractive to investors. Even if we implement the Reverse Stock Split,
the per share trading price of our common stock may decrease due to factors unrelated to the Reverse Stock Split, including our future
performance. If the Reverse Stock Split is consummated and the per share trading price of our common stock declines, the percentage decline
as an absolute number and as a percentage of our overall market capitalization may be greater than would occur in the absence of the
Reverse Stock Split. Despite approval of the Reverse Stock Split by our stockholders and the implementation thereof by our Board of Directors,
there is no assurance that the price of our common stock would be, or remain, following the Reverse Stock Split at a level high enough
to enable us to comply with the Minimum Bid Requirement or to attract capital investment in our company.
The
proposed Reverse Stock Split may decrease the liquidity of our common stock and result in higher transaction costs. The liquidity
of our common stock may be negatively impacted by the Reverse Stock Split, given the reduced number of shares that will be outstanding
after the Reverse Stock Split, particularly if the per share trading price does not increase as a result of the Reverse Stock Split.
In addition, if the Reverse Stock Split is implemented, it may increase the number of our stockholders who own “odd lots”
of fewer than 100 shares of common stock. Brokerage commissions and other costs of transactions in odd lots are generally higher than
the costs of transactions of more than 100 shares of common stock. Accordingly, the Reverse Stock Split may not result in increasing
the marketability of our common stock.
Effects
of the Reverse Stock Split
General
The
principal effect of the Reverse Stock Split, if implemented by the Board, would be to proportionately decrease the number of issued and
outstanding shares of our common stock based on the ratio selected by our Board, which will result in each stockholder owning a reduced
number of shares of common stock after the effective date of the Reverse Stock Split. The actual number of shares issued and outstanding
and ultimately owned by each stockholder after giving effect to the Reverse Stock Split, if implemented, would depend on the ratio for
the Reverse Stock Split that is ultimately determined by our Board. The Reverse Stock Split would affect all holders of our common stock
uniformly and would not affect any stockholder’s percentage ownership interest in the Company, except that, as described below
under “Mechanics of the Reverse Stock Split-Fractional Shares,” In addition, the Reverse Stock Split would not affect any
stockholder’s proportionate voting power, subject to the treatment of fractional shares.
The
Reverse Stock Split may result in some stockholders owning “odd lots” of less than 100 shares of common stock. Odd lot shares
may be more difficult to sell, and brokerage commissions and other costs of transactions in odd lots may be higher than the costs of
transactions in “round lots” of even multiples of 100 shares.
After
the effective time of the Reverse Stock Split, our common stock will have a new Committee on Uniform Securities Identification Procedures,
or CUSIP, number, which is a number used to identify our common stock.
Effect
on Capital Stock
The
Company is authorized to issue 490,000,000 shares of common stock, par value $0.0001 per share, and 5,000,000 shares of preferred stock,
which includes (x) 15,000 shares that have been designated as Series A Convertible Preferred Stock, at a stated value equal to $1,000
per share, and (y) 15,000 shares that have been designated as Series B Convertible Preferred Stock, at a stated value equal to $1,000
per share, the terms of which are to be determined, from time to time, by our board of directors. The proposed Reverse Stock Split will
have no impact on the total authorized number of shares of common stock or preferred stock, or the par value of the common stock or preferred
stock.
Accounting
Matters
As
a result of the Reverse Stock Split, at the effective time of the Reverse Stock Split, the stated capital on the Company’s balance
sheet attributable to our common stock, which consists of the par value per share of our common stock multiplied by the aggregate number
of shares of our common stock issued and outstanding, will be reduced in proportion to the Reverse Stock Split ratio chosen by the Board.
Correspondingly, the Company’s additional paid-in capital account, which consists of the difference between the Company’s
stated capital and the aggregate amount paid to the Company upon issuance of all currently outstanding shares of common stock, will be
credited with the amount by which the stated capital is reduced. The Company’s stockholders’ equity, in the aggregate, will
remain unchanged. The historical earnings or loss per share of our common stock reported in all financial reports published after the
effective date of the Reverse Stock Split will be restated to reflect the proportionate decrease in the number of outstanding shares
of common stock for all periods presented so that the results are comparable.
Mechanics
of the Reverse Stock Split
In
the case of common stock registered directly on the books of Vstock Transfer LLC, our transfer agent, only, no fractional shares of common
stock will be issued as a result of the Reverse Stock Split. Rather, any fractional shares will be rounded up to the next higher whole
share.
In
the case of common stock held through a broker, bank or nominee, your broker, bank, or nominee will determine the process for dealing
with any entitlements to fractional shares of common stock.
Upon
the effectiveness of the Reverse Stock Split, we intend to treat shares of common stock held by stockholders in “street name,”
through a bank, broker, or other nominee, in the same manner as registered stockholders whose shares of common stock are registered in
their names. Banks, brokers, or other nominees will be instructed to effectuate the Reverse Stock Split for their beneficial holders
holding the common stock in “street name.” However, these banks, brokers or other nominees may have different procedures
than registered stockholders for processing the Reverse Stock Split. If a stockholder holds shares of common stock with a bank, broker
or other nominee and has any questions in this regard, stockholders are encouraged to contact their bank, broker, or other nominee.
Effect
on Registered “Book-Entry” Holders of Common Stock (i.e., stockholders that are registered on the transfer agent’s
books and records)
All
of our registered holders of common stock hold their shares electronically in book-entry form with our transfer agent. They are provided
with a statement reflecting the number of shares registered in their accounts.
If
a stockholder holds registered shares in book-entry form with the transfer agent, no action needs to be taken to receive post-Reverse
Stock Split shares. If a stockholder is entitled to post-Reverse Stock Split shares, a transaction statement will automatically be sent
to the stockholder’s address of record indicating the number of shares of common stock held following the Reverse Stock Split.
Effective
Time
The
effective time of the Reverse Stock Split, if the proposed Reverse Stock Split Amendment is adopted and approved by stockholders and
the Reverse Stock Split is implemented at the direction of the Board, will be the date and time that the Reverse Stock Split Amendment
effecting the amendment with the ratio selected by the Board is filed with the Delaware Secretary of State or such later time as is specified
therein. Such filing may occur as soon as the day of the Annual Meeting or at any time prior to the one-year anniversary of stockholder
approval of the Reverse Stock Split. The exact timing of the Reverse Stock Split will be determined by our Board based on its evaluation
as to when such action will be the most advantageous to the Company and its stockholders, and the effective date will be publicly announced
by the Company.
The Board reserves the right to withdraw Proposal
No. 4 relating to the Reverse Stock Split and, if such proposal is withdrawn, all references in the Company’s proxy materials to
voting for Proposal No. 4 should be disregarded. In addition, the Reverse Stock Split may be delayed or abandoned without further action
by the stockholders at any time prior to effectiveness of the Reverse Stock Split Amendment with the Delaware Secretary of State, notwithstanding
stockholder adoption and approval of the Reverse Stock Split Amendment, if the Board, in its sole discretion, determines that it is in
the best interests of the Company and its stockholders to delay or abandon the Reverse Stock Split. If the Reverse Stock Split Amendment
implementing the Reverse Stock Split has not been filed with the Delaware Secretary of State on or before the one-year anniversary of
stockholder approval of the Reverse Stock Split, the Board will be deemed to have abandoned the Reverse Stock Split.
Appraisal
Rights
Under
Delaware law, our stockholders are not entitled to dissenter’s rights or appraisal rights with respect to the Reverse Stock Split
and we will not independently provide our stockholders with any such rights.
Certain
U.S. Federal Income Tax Consequences of the Reverse Stock Split
The
following discussion is a general summary of certain U.S. federal income tax consequences of the Reverse Stock Split that may be relevant
to stockholders for U.S. federal income tax purposes. This summary is based upon the provisions of the Code, Treasury Regulations promulgated
thereunder, administrative rulings and judicial decisions as of the date of this proxy statement, all of which may change, possibly with
retroactive effect, resulting in U.S. federal income tax consequences that may differ from those discussed below.
This
discussion applies only to holders of our common stock that are U.S. Holders (as defined below) and does not address all aspects of federal
income taxation that may be relevant to such holders in light of their particular circumstances or to holders that may be subject to
special tax rules, including: (i) holders subject to the alternative minimum tax; (ii) banks, insurance companies, or other financial
institutions; (iii) tax-exempt organizations; (iv) dealers in securities or commodities; (v) regulated investment companies or real estate
investment trusts; (vi) partnerships (or other flow-through entities for U.S. federal income tax purposes and their partners or members);
(vii) traders in securities that elect to use a mark-to-market method of accounting for their securities holdings; (viii) U.S. Holders
whose “functional currency” is not the U.S. dollar; (ix) persons holding our common stock as a position in a hedging transaction,
“straddle,” “conversion transaction” or other risk reduction transaction; (x) persons who acquire shares of our
common stock in connection with employment or other performance of services; or (xi) U.S. expatriates. If a partnership (including any
entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds shares of our common stock, the tax treatment
of a holder that is a partner in the partnership generally will depend upon the status of the partner and the activities of the partnership.
We
have not sought, and will not seek, an opinion of counsel or a ruling from the Internal Revenue Service (“IRS”) regarding
the U.S. federal income tax consequences of the Reverse Stock Split and there can be no assurance that the IRS will not challenge the
statements and conclusions set forth below or that a court would not sustain any such challenge. The following summary does not address
any U.S. state or local or any foreign tax consequences, any estate, gift or other non-U.S. federal income tax consequences, or the Medicare
tax on net investment income.
EACH
HOLDER OF COMMON STOCK SHOULD CONSULT SUCH HOLDER’S OWN TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES OF THE REVERSE
STOCK SPLIT TO SUCH HOLDER.
For
purposes of the discussion below, a “U.S. Holder” is a beneficial owner of shares of our common stock that for U.S. federal
income tax purposes is: (1) an individual citizen or resident of the United States; (2) a corporation (including any entity taxable as
a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, or any state or political
subdivision thereof; (3) an estate the income of which is subject to U.S. federal income taxation regardless of its source; or (4) a
trust, if (i) a court within the United States is able to exercise primary supervision over the administration of the trust and one or
more U.S. persons have the authority to control all substantial decisions of the trust or (ii) the trust has a valid election in effect
to be treated as a U.S. person.
The
Board intends the Reverse Stock Split to be treated as a “recapitalization” under Section 368(a)(1)(E) of the Code, although
no assurances are provided in this regard. In such case, we should not recognize gain or loss in connection with the Reverse Stock Split.
Also, a U.S. Holder generally should not recognize gain or loss upon the Reverse Stock Split. A U.S. Holder’s aggregate tax basis
in the shares of our common stock received pursuant to the Reverse Stock Split should equal the aggregate tax basis of the shares of
our common stock surrendered (excluding any portion of such basis that is allocated to any fractional share of our common stock), and
such U.S. Holder’s holding period in the shares of our common stock received should include the holding period in the shares of
our common stock surrendered. Holders of shares of our common stock acquired on different dates and at different prices should consult
their own tax advisors regarding the allocation of the tax basis and holding period of such shares.
Vote
Required
Adoption of Proposal No. 4 requires an affirmative
vote of a majority of the outstanding common stock entitled to vote thereon. You may vote “FOR,” “AGAINST,” or
“ABSTAIN” from voting concerning Proposal No. 4. Abstentions will count toward the quorum and will have the same effect as
a vote against Proposal No. 4. Approval of Proposal No. 4 is not conditioned upon approval of any other proposal.
Recommendation
THE
BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE “FOR” THE REVERSE STOCK SPLIT PROPOSAL.
PROPOSAL
NO. 5: APPROVAL OF AMENDMENT TO CERTIFICATE OF INCORPORATION TO DECREASE THE TOTAL NUMBER OF AUTHORIZED SHARES FROM 490,000,000
SHARES TO 100,000,000 SHARES
We are asking stockholders to adopt and approve
an amendment to our Certificate of Incorporation, which approval is contingent upon stockholder approval or, and the effectuation of,
the Reverse Stock Split (see Proposal No. 4), to decrease the total number of authorized shares of our common stock from 490,000,000 shares
to 100,000,000 shares (the “Decrease in Authorized Shares Amendment”). On [●], 2024, our Board unanimously approved and
declared advisable the proposed Decrease in Authorized Shares Amendment, and recommends that our stockholders adopt and approve Proposal
No. 5 and the proposed Decrease in Authorized Shares Amendment. If stockholders approve Proposal No. 4 and the Reverse Stock Split is
effectuated, and if this Proposal No. 5 is approved by stockholders, this Proposal No. 5 will authorize the amendment of our Certificate
of Incorporation to effectuate the Authorized Share Decrease, decreasing our authorized shares of common stock from 490,000,000 shares
of common stock to 100,000,000 shares of common stock.
Assuming stockholders approve Proposal No. 4,
the Reverse Stock Split is effectuated, and stockholders approve this Proposal No. 5, the effective date of the Authorized Share Decrease
will be determined at the sole discretion of the Board, and may occur as soon as the day of the Annual Meeting. The effective date of
the Authorized Share Decrease will be publicly announced by us. The Board may determine, in its sole discretion, not to effectuate the
Authorized Share Decrease and not to file any amendment to our Certificate of Incorporation.
Our Board of Directors’ primary reason for
approving and recommending the Reverse Stock Split (Proposal No. 4) is to increase the share price of our common stock. If the Reverse
Stock Split is effectuated and the price per share of our common stock increases, the number of shares of common stock potentially required
to cover exercise of the Warrants, conversion of the Notes and/or any other conversions, will be lower because fewer shares would be required
for conversions. Therefore, assuming that the price per share of our common stock increases due to the Reverse Stock Split, the Board
of Directors believes authorizing more than 100,000,000 shares of common stock for issuance would no longer be advisable or necessary
at this time. The Board of Directors believes that if the number of authorized shares of common stock is decreased, it may have the effect
of making investment in our common stock more attractive to investors because the risk of dilution by issuance of additional shares is
more limited. Accordingly, the Board believes that at a higher share price, authorizing 501,000,000 shares of common stock will provide
us with the ability and flexibility desired.
We do not have any definitive plans, arrangements,
understandings or agreements regarding the potential implications of decreasing the authorized shares of common stock. We are asking stockholders
to approve the Decrease in Authorized Shares Amendment which, if approved by stockholders and the Reverse Stock Split occurs, will authorize
the amendment of our Certificate of Incorporation to effectuate the Authorized Share Decrease from 490,000,000 shares of common stock
to 100,000,000 shares of common stock.
The adoption of the Decrease in Authorized Shares
Amendment would not have any immediate accretive effect on the proportionate voting power or other rights of existing stockholders. However,
future issuance of additional authorized shares of our common stock would be more limited than would be the case if 490,000,000 shares
of common stock were authorized for issuance.
Board Discretion to Implement the Authorized
Share Decrease
The Board believes that stockholder adoption and
approval of the Authorized Share Decrease is in the best interests of our stockholders. If our stockholders approve this Proposal No.
5, the Board will implement the Authorized Share Decrease only upon (i) approval of Proposal No. 4 by stockholders, (ii) effectuation
of the Reverse Stock Split, and (iii) a determination that the Authorized Share Decrease is in the best interests of the stockholders
at that time. The Board may abandon the Authorized Share Decrease in its sole discretion.
Effective Time
The effective time of the Authorized Share Decrease
(if Proposal No. 4 is approved by stockholders, the Reverse Stock Split is effectuated, the proposed Decrease in Authorized Shares Amendment
is adopted and approved by stockholders, and the Authorized Share Decrease is implemented at the discretion of the Board) will be the
date and time that the Certificate of Incorporation amendment effectuating the Authorized Share Decrease is filed with the Delaware Secretary
of State or such later time as is specified therein. Such filing may occur as soon as the day of the Annual Meeting or at any time prior
to the 2025 annual meeting of stockholders. The exact timing of the Authorized Share Decrease will be determined by our Board based on
its evaluation as to when such action will be the most advantageous to the Company and its stockholders, and the effective date will be
publicly announced by the Company.
The Authorized Share Decrease may be delayed or
abandoned without further action by the stockholders at any time prior to effectiveness of the relevant Certificate of Incorporation amendment
with the Delaware Secretary of State, notwithstanding stockholder adoption and approval of the Decrease in Authorized Shares Amendment
and/or stockholder approval of the Reverse Stock Split and/or effectuation of the Reverse Stock Split, if the Board, in its sole discretion,
determines that it is in the best interests of the Company and its stockholders to delay or abandon the Authorized Share Decrease. If
the Certificate of Incorporation amendment implementing the Authorized Share Decrease is not effective with the Delaware Secretary of
State on or before the date of the 2025 Annual Meeting, the Board will be deemed to have abandoned the Authorized Share Decrease.
Vote Required
The affirmative vote of the holders of a majority
of the outstanding shares of common stock entitled to vote at the Annual Meeting is required to adopt and approve the Decrease in Authorized
Shares Amendment. You may vote “FOR,” “AGAINST” or “ABSTAIN” from voting on Proposal No. 5. Abstentions
and broker non-votes will have the effect of a vote “against” Proposal No. 5.
THE BOARD OF DIRECTORS
UNANIMOUSLY RECOMMENDS THAT YOU VOTE FOR PROPOSAL NO. 5.
PROPOSAL NO. 6: ADVISORY VOTE ON EXECUTIVE
COMPENSATION
Under
the Dodd-Frank Act and Section 14A of the Exchange Act, our stockholders are entitled to vote to approve, on an advisory (non-binding)
basis, the compensation of our Named Executive Officers as disclosed in this Proxy Statement in accordance with the SEC’s rules.
Our
executive compensation program is designed to retain and incentivize the high-quality executives whose efforts are key to our long-term
success. Under these programs, our Named Executive Officers are rewarded on the basis of individual and corporate performance measured
against established corporate and strategic goals.
The
Compensation Committee continually reviews the compensation programs for our Named Executive Officers to ensure they achieve the desired
goals of aligning our executive compensation structure with our stockholders’ interests and current market practices.
We
are asking our stockholders to indicate their support for our Named Executive Officers’ compensation as described in this Proxy
Statement. This proposal, commonly known as a “Say-on-Pay” proposal, gives our stockholders the opportunity to express their
views on our Named Executive Officer’s compensation. This vote is not intended to address any specific item of compensation, but
rather the overall compensation of our Named Executive Officers and the philosophy, policies and practices described in this Proxy Statement.
Accordingly, we are asking our stockholders to cast a non-binding advisory vote “FOR” the following resolution at the Annual
Meeting:
“RESOLVED,
that the compensation of the Named Executive Officers, as disclosed in the Company’s Proxy Statement for the 2024 Annual Meeting
of Stockholders pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative disclosure is hereby APPROVED.”
Required
Vote and Recommendation
The
Say-on-Pay vote is advisory, and therefore not binding on, Avalon, our Board or our Compensation Committee. Nevertheless, our Board and
our Compensation Committee value the opinions of our stockholders, whether expressed through this vote or otherwise, and accordingly,
the Board and our Compensation Committee intend to consider the results of this vote among the many factors they consider in making determinations
in the future regarding executive compensation arrangements.
THE
BOARD RECOMMENDS A VOTE “FOR” THE ADVISORY VOTE ON EXECUTIVE COMPENSATION.
STOCKHOLDER
PROPOSALS
Stockholder
Proposals for 2025 Annual Meeting
Any
stockholder proposals submitted for inclusion in our proxy statement and form of proxy for our 2025 Annual Meeting of Stockholders in
reliance on Rule 14a-8 under the Exchange Act must be received by us no later than April 30, 2025 in order to be considered for inclusion
in our proxy statement and form of proxy. Such proposal must also comply with the requirements as to form and substance established by
the SEC if such proposals are to be included in the proxy statement and form of proxy. Any such proposal shall be mailed to: Avalon GloboCare
Corp., 4400 Route 9 South, Suite 3100, Freehold, New Jersey 07728, Attn.: Secretary.
Our
bylaws state that a stockholder must provide timely written notice of any nominations of persons for election to our Board or any other
proposal to be brought before the annual meeting together with supporting documentation as well as be present at such meeting, either
in person or by representative. For our 2025 Annual Meeting of Stockholders, a stockholder’s notice shall be timely received by
us at our principal executive office no later July 10, 2025 and no earlier than June 10, 2025; provided, however, that in the
event the annual meeting is scheduled to be held more than 30 days before the anniversary date of the immediately preceding annual meeting
(the “Anniversary Date”) or more than 60 days after the Anniversary Date, a stockholder’s notice shall be timely if
received by our Secretary at our principal executive office not later than the close of business on the later of (i) the 90th day prior
to the scheduled date of such annual meeting; and (ii) the 10th day following the day on which such public announcement of the date of
such annual meeting is first made by us. Proxies solicited by our Board will confer discretionary voting authority with respect to these
nominations or proposals, subject to the SEC’s rules and regulations governing the exercise of this authority. Any such nomination
or proposal shall be mailed to: Avalon GloboCare Corp., 4400 Route 9 South, Suite 3100, Freehold, New Jersey 07728, Attn.: Secretary.
Further,
if you intend to nominate a director and solicit proxies in support of such director nominee(s) at the 2025 Annual Meeting of Stockholders,
you must also provide the notice and additional information required by Rule 14a-19 to: Avalon GloboCare Corp., 4400 Route 9 South, Suite
3100, Freehold, New Jersey 07728, Attn.: Secretary, no later than August 9, 2025. This deadline under Rule 14a-19 does not supersede
any of the timing requirements for advance notice under our bylaws. The supplemental notice and information required under Rule 14a-19
is in addition to the applicable advance notice requirements under our bylaws as described in this section and it shall not extend any
such deadline set forth under our bylaws.
ANNUAL
REPORT
A
copy of our 2023 Annual Report on Form 10-K (including our audited financial statements) filed with the SEC is enclosed herewith. Upon
written request to the Company, the exhibits set forth on the exhibit index of our Annual Report on Form 10-K may be made available at
a reasonable charge (which will be limited to our reasonable expenses in furnishing such exhibits). Additional copies of our 2023 Annual
Report on Form 10-K (including our audited financial statements) may be obtained without charge by writing to Avalon GloboCare Corp.,
4400 Route 9 South, Suite 3100, Freehold, New Jersey, 07728, Attn.: Secretary.
HOUSEHOLDING
OF ANNUAL MEETING MATERIALS
Some
banks, brokers and other nominee record holders may be participating in the practice of “householding” proxy statements.
This means that only one copy of this Proxy Statement may have been sent to multiple stockholders in the same household. We will promptly
deliver a separate copy of this Proxy Statement to any stockholder upon written or oral request to: Avalon GloboCare Corp., 4400 Route
9 South, Suite 3100, Freehold, NJ 07728, Attn.: Secretary, or by phone at (732) 780-4400. Any stockholder who wants to receive a separate
copy of this Proxy Statement, or of our proxy statements or annual reports in the future, or any stockholder who is receiving multiple
copies and would like to receive only one copy per household, should contact the stockholder’s bank, broker, or other nominee record
holder, or the stockholder may contact us at the address and phone number above.
OTHER
MATTERS
As
of the date of this Proxy Statement, the Board does not intend to present at the Annual Meeting of any matters other than those described
herein and does not presently know of any matters that will be presented by other parties. If any other matter requiring a vote of the
stockholders should come before the Annual Meeting, it is the intention of the persons named in the proxy to vote with respect to any
such matter in accordance with the recommendation of the Board or, in the absence of such a recommendation, in accordance with the best
judgment of the proxy holder.
|
By
Order of the Board of Directors |
|
|
|
/s/
Wenzhao Lu |
|
Name: |
Wenzhao Lu |
|
Title: |
Chairman of the Board of Directors |
[●],
2024 |
Freehold,
New Jersey |
40
Avalon GloboCare (NASDAQ:ALBT)
Gráfico Histórico do Ativo
De Jul 2024 até Ago 2024
Avalon GloboCare (NASDAQ:ALBT)
Gráfico Histórico do Ativo
De Ago 2023 até Ago 2024